

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number
WO 02/055098 A2

(51) International Patent Classification⁷: **A61K 38/00**

dicine and Dentistry, Charterhouse Square, London EC1M 6BQ (GB).

(21) International Application Number: PCT/GB02/00068

(22) International Filing Date: 9 January 2002 (09.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0100551.1 9 January 2001 (09.01.2001) GB

(71) Applicant (*for all designated States except US*): **QUEEN MARY & WESTFIELD COLLEGE** [GB/GB]; Mile End Road, London E1 4NS (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CHERNAJOVSKY, Yuti** [GB/GB]; Bone and Joint Research Unit, St Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ (GB). **DREJA, Hanna, Stina** [SE/FR]; Bone and Joint Research Unit, St Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ (GB). **ADAMS, Gillian** [GB/GB]; Bone and Joint Research Unit, St Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ (GB).

(74) Agents: **BASSIL, Nicholas, Charles** et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR PROVIDING LATENCY TO PHARMACEUTICALLY ACTIVE AGENTS

(57) Abstract: The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytically cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.



WO 02/055098 A2

Method For Providing Latency To Pharmaceutically Active Agents

The present invention relates to the use of proteins, protein derivatives and DNA constructs that confer latency to pharmaceutically active agents. The present invention also relates to methods of providing latency to pharmaceutically active agents and to methods of providing site specific activation to latent pharmaceutically active agents.

Most cytokines and growth factors are expressed under tight control mechanisms. Their gene expression is regulated by environmental stimuli such as infection, cell-cell interactions, change in extracellular matrix composition and interactions with adhesion molecules or via stimulation with other cytokines.

In addition to the control at the transcriptional and post-transcriptional level, some cytokines are not released into the medium unless a second signal activates the cell. A third level of regulation for cytokine activity is found in molecules which are secreted in a latent form and become "activated" by releasing the cytokine moiety where processes of inflammation, wound healing and tissue repair takes place (Khalil N, *Microbes and Infection*, **1**, 1255-1263 (1999)). In this latter respect, transforming growth factor beta (TGF β) has received greatest attention.

TGF β is synthesized as a dimeric latent cytokine -composed of an amino terminal latency associated protein (LAP) and the active TGF β cytokine at its COOH terminal end (Roberts and Sporn, *Peptide Growth Factors and their Receptors*: Sporn, MB and Roberts, AB, Springer-Verlag, 419-472 (1996); Roth-Eicchorn et al., *Hepatology*, **28** 1588-1596 (1998)). The precursor peptide contains a signal peptide (residues 1-29) necessary for protein secretion and guiding the molecule through the Golgi apparatus to become processed by proteolytic cleavage and glycosylation. The LAP domain is separated from TGF β by proteolytic cleavage at arginines (277-278). Mature TGF β begins at alanine 279. The LAP, in addition to protect TGF β , contains important residues necessary for the interaction with other molecules. Mutations in the LAP domain have recently been associated with the autosomal dominant Camurati-Engelmann disease (Janssens et al., *Nature Genetics*, **26**, 273-275 (2000)). Cysteines 224 and 226 are important in the intermolecular disulphide bond between two LAPs.

Their mutation to serine renders the molecule "active" (Sanderson et al., Proc. Natl. Acad. Sci. USA, **92**, 2572-2576 (1995); Brunner et al., Mol. Endocrinol. **6**, 1691-1700 (1992); Brunner et al., J. Biol. Chem, **264**, 13660-13664 (1989)). The RGD motif (245-247) facilitates the interaction with integrins (Munger et al., Mol. Biol. of the Cell, **9**, 2627-2638 (1998; Derynck R, TIBS, **19**, 548-553 (1994)). Nucleic acid encoding TGF β is described in US 5801231.

In most cell types studied, including those of mesenchymal, epithelial and endothelial origin, TGF β is secreted in a latent form consisting of TGF β and its latency associated peptide (LAP) propeptide dimers, covalently linked to latent TGF β -binding proteins (LTBPs). LTBPs are also needed for the secretion and folding of TGF β (Miyazano et al., EMBO J. **10**, 1091-1101 (1991); Miyazano et al., J. Biol. Chem. **267**, 5668-5675 (1992); Eklov et al., Cancer Res. **53**, 3193-3197 (1993)). Cysteine 33 is important for the disulphide bridge with the third 8 cysteine-rich repeat of latent TGF β binding protein (LTBP) (Saharinen et al., The EMBO Journal, **15**, 245-253 (1996). Modification of LTBP by enzymes such as thrombospondin (Schultz et al., The Journal of Biological Chemistry, **269**, 26783-26788 (1994); Crawford et al., Cell, **93**, 1159-1170 (1998)), transglutaminase (Nunes et al., J. Cell, Biol. **136**, 1151-1163 (1997); Kojima et al., The Journal of Cell Biology, **121**, 439-448 (1993)) and MMP9, MMP2 (Yu and Stamenkovic, Genes and Dev, **14**, 163-176 (2000)) could release the active portion of TGF β from the latent complex.

Cytokines are natural products serving as soluble local mediators of cell-cell interactions. They have a variety of pleiotropic actions, some of which can be harnessed for therapeutic purposes. Targeting of cytokines to specific cell types using scFv (Lode et al., Pharmacol. Ther, **80**, 277-292 (1998)) and vWF (Gordon et al., Human Gene Therapy, **8**, 1385-1394 (1997)) have focused entirely on the active cytokine moiety of the cytokine complex.

Pharmacologically active proteins or other medicines based on such agents, which have to be administered at very high concentrations systemically in order to achieve biologically effective concentrations in the tissue being targeted, tend to give rise to undesirable systemic effects, for example toxicity, which limit their use and efficacy.

The present inventors have developed a system for overcoming the toxic effect of systemic administration of potent biological agents.

According to a first aspect of the invention there is provided the use of a fusion protein comprising a latency associated peptide (LAP) and a proteolytic cleavage site for providing latency to a pharmaceutically active agent.

The first aspect of the invention also provides the use of a fusion protein comprising a LAP and a proteolytic cleavage site for providing site specific activation to a latent biologically active agent. The term "site specific activation" as used herein means, in general terms and not limited to the removal or reduction of latency, conferred on a pharmaceutically active agent, by site specific cleavage at the proteolytic cleavage site.

Site specific cleavage at the proteolytic cleavage site is expected to take place concomitantly with the restored activation of the pharmaceutically active agent.

The term "latent biologically active agent" as used herein may include, but is not limited to, biologically active agents which are latent due to their association with LAP and a proteolytic cleavage site. Specifically, the biologically active agent may be latent by virtue of its fusion to a LAP associated proteolytic cleavage site to form a latent fusion protein.

According to a second aspect of the invention there is provided a method of providing latency to a pharmaceutically active agent comprising associating a fusion protein comprising a latency associated peptide (LAP) and a proteolytic cleavage site with said pharmaceutically active agent.

The term "protein" in this text means, in general terms, a plurality of amino acid residues joined together by peptide bonds. It is used interchangeably and means the same as peptide, oligopeptide, oligomer or polypeptide, and includes glycoproteins and derivatives thereof. The term "protein" is also intended to include fragments, analogues and derivatives of a protein wherein the fragment, analogue or derivative retains essentially the same biological activity or function as a reference protein.

The fragment analogue or derivative of the protein as defined in this text, may be at least 6, preferably 10 or 20, or up to 50 or 100 amino acids long.

The fragment, derivative or analogue of the protein may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably, a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence which is employed for purification of the polypeptide. Such fragments, derivatives and analogues are deemed to be within the scope of those skilled in the art from the teachings herein.

Particularly preferred are variants, analogues, derivatives and fragments having the amino acid sequence of the protein in which several e.g. 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein of the present invention. Also especially preferred in this regard are conservative substitutions.

An example of a variant of the present invention is a fusion protein as defined above, apart from the substitution of one or more amino acids with one or more other amino acids. The skilled person is aware that various amino acids have similar properties. One or more such amino acids of a substance can often be substituted by one or more other such amino acids without eliminating a desired activity of that substance.

Thus the amino acids glycine, alanine, valine, leucine and isoleucine can often be substituted for one another (amino acids having aliphatic side chains). Of these possible substitutions it is preferred that glycine and alanine are used to substitute for one another (since they have relatively short side chains) and that valine, leucine and isoleucine are used to substitute for one another (since they have larger aliphatic side chains which are hydrophobic). Other amino acids which can often be substituted for one another

include: phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino acids having acidic side chains); asparagine and glutamine (amino acids having amide side chains); and cysteine and methionine (amino acids having sulphur containing side chains).

Substitutions of this nature are often referred to as "conservative" or "semi-conservative" amino acid substitutions.

Amino acid deletions or insertions may also be made relative to the amino acid sequence for the fusion protein referred to above. Thus, for example, amino acids which do not have a substantial effect on the activity of the polypeptide, or at least which do not eliminate such activity, may be deleted. Such deletions can be advantageous since the overall length and the molecular weight of a polypeptide can be reduced whilst still retaining activity. This can enable the amount of polypeptide required for a particular purpose to be reduced - for example, dosage levels can be reduced.

Amino acid insertions relative to the sequence of the fusion protein above can also be made. This may be done to alter the properties of a substance of the present invention (e.g. to assist in identification, purification or expression, as explained above in relation to fusion proteins).

Amino acid changes relative to the sequence given in a) above can be made using any suitable technique e.g. by using site-directed mutagenesis.

It should be appreciated that amino acid substitutions or insertions within the scope of the present invention can be made using naturally occurring or non-naturally occurring amino acids. Whether or not natural or synthetic amino acids are used, it is preferred that only L- amino acids are present.

A protein according to the invention may have additional N-terminal and/or C-terminal amino acid sequences. Such sequences can be provided for various reasons, for example, glycosylation.

The term "fusion protein" in this text means, in general terms, one or more proteins joined together by chemical means, or by peptide bonds through protein synthesis or both.

The latency associated peptide (LAP) of the present invention may include, but is not limited to, the coding sequence for the precursor domain of TGF β or a sequence which is substantially identical thereto.

"Identity" as known in the art is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. While there exist a number of methods to measure identity between two polypeptide or two polynucleotide sequences, methods commonly employed to determine identity are codified in computer programs. Preferred computer programs to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, et al., *Nucleic acids Research*, **12**, 387 (1984), BLASTP, BLASTN, and FASTA (Atschul et al., *J. Molec. Biol.* **215**, 403 (1990)).

The LAP of the present invention may comprise the precursor domain of TGF β , for example, the precursor peptide of TGF β -1, 2 or 3 (from human) (Derynck et al., *Nature*, **316**, 701-705 (1985); De Martin et al., *EMBO J.* **6** 3673-3677 (1987); Hanks et al., *Proc. Natl. Acad. Sci.* **85**, 79-82 (1988); Derynck et al., *EMBO J.* **7**, 3737-3743 (1988); Ten Dyke et al., *Proc. Natl. Acad. Sci. USA*, **85**, 4715-4719 (1988)) TGF β -4 (from chicken) (Jakowlew et al., *Mol. Endocrinol.* **2**, 1186-1195 (1988)) or TGF β -5 (from xenopus) (Kondaiah et al., *J. Biol. Chem.* **265**, 1089-1093 (1990)). The term "precursor domain" is defined as a sequence encoding a precursor peptide which does not include the sequence encoding the mature protein. The amino acid sequences of the precursor domain of TGF β 1, 2, 3, 4 and 5 (Roberts and Sporn, *Peptide Growth Factors and their Receptors*: Sporn, MB and Roberts, AB, Springer-Verlag, Chapter 8, 422 (1996)) are shown in Figure 3.

Preferably, the amino acid sequence of the LAP has at least 50% identity, using the default parameters of the BLAST computer program (Atschul et al., J. Mol. Biol. **215**, 403-410 (1990) provided by HGMP (Human Genome Mapping Project), at the amino acid level, to the precursor domain of TGF β 1, 2, 3, 4 or 5 (Roberts and Sporn, Peptide Growth Factors and their Receptors: Sporn, MB and Roberts, AB, Springer-Verlag, Chapter 8, 422 (1996)) as shown in Figure 3. More preferably, the LAP may have at least 60%, 70%, 80%, 90% and still more preferably 95% (still more preferably at least 99%) identity, at the nucleic acid or amino acid level, to the precursor domain of TGF β 1, 2, 3, 4 or 5 as shown in Figure 3.

The LAP may comprise the LAP of TGF β 1, 2, 3, 4, or 5 (Roberts and Sporn, Peptide Growth Factors and their Receptors: Sporn, MB and Roberts, AB, Springer-Verlag, Chapter 8, 422 (1996)) as shown in Figure 3.

The LAP may contain at least two, for example at least 4, 6, 8, 10 or 20 cysteine residues for the formation of disulphide bonds.

The LAP may provide a protective "shell" around the pharmaceutically active agent thereby shielding it and hindering, or preventing, its interaction with other molecules in the cell surface or molecules important for its activity.

The LAP may comprise the sequence of amino acids encoded by nucleotides 1-832 of Figure 1 or nucleotides 598-1352 of Figure 2 or a sequence which has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% identity, using the default parameters of the BLAST computer program provided by HGMP, thereto.

The proteolytic cleavage site may comprise any protease specific cleavage site. The proteolytic cleavage site may include, but is not limited to, a matrix metalloproteinase (MMP) cleavage site, a serine protease cleavage site, a site cleavable by a parasitic protease derived from a pathogenic organism (Zhang et al., J. Mol. Biol. **289**, 1239-1251 (1999); Voth et al., Molecular and Biochemical Parasitology, **93**, 31-41 (1998); Yoshioka et al., Folia Pharmacologica Japonica, **110**, 347-355 (1997); Tort et al., Advances in Parasitology, **43**, 161-266 (1999); McKerrow, International Journal for

Parasitology, **29**, 833-837 (1999); Young et al., International Journal for Parasitology, **29**, 861-867 (1999); Coombs and Mottram, Parasitology, **114**, 61-80 (1997)) or a site cleavable by the proteins of the complement cascade (Carroll, Annu. Rev. Immunol. **16**, 545-568 (1998); Williams et al., Ann. Allergy, **60**, 293-300 (1988)).

The MMP cleavage site may comprise any amino acid sequence which is cleavable by a MMP. The amino acid sequence of the MMP cleavage site may be encoded by nucleotides 844-861 of Figure 1 or nucleotides 565-585 of Figure 2 or a sequence of nucleotides which has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% identity, using the default parameters of the BLAST computer program provided by HGMP, thereto. Preferably, the nucleic acid sequence encoding the MMP cleavage site comprises the minimum number of residues required for recognition and cleavage by MMP.

A MMP cleavage site may comprise a number of amino acid residues recognisable by MMP. Moreover, the amino acids of the MMP site may be linked by one or more peptide bonds which are cleavable, proteolytically, by MMP. MMPs which may cleave the MMP site include, but are not limited to, MMP1, MMP2, MMP3, MMP7, MMP8, MMP9 or MMP10 (Yu and Stamenkovic, Genes and Dev. **14**, 163-176 (2000); Nagase and Fields, Biopolymers, **40**, 399-416 (1996); Massova et al., J. Mol. Model. **3**, 17-30 (1997); reviewed in Vu and Werb, Genes and Dev. **14**, 2123-2133 (2000)). The sequences of the protein cleavage sites of MMP1, MMP2, MMP3, MMP7, MMP8, MMP9 and MMP10 are shown in Figure 4.

Preferably, the proteolytic cleavage site of the present invention is cleaved at sites of inflammation and tissue remodelling. More preferably, the proteolytic cleavage site of the present invention is a MMP cleavage site e.g any one or more of MMP1, MMP2, MMP3, MMP7, MMP8, MMP9 or MMP10 as shown in Figure 4.

The invention further provides nucleic acid encoding the fusion protein of the first and second aspects of the invention. The nucleic acid encoding the fusion protein may comprise nucleotides 1-861 of Figure 1 or nucleotides 585-1352 of Figure 2 or a sequence of nucleotides which has at least 50%, 60%, 70%, 80%, 90%, 95% or 99%

identity, using the default parameters of the BLAST computer program provided by HGMP, thereto.

The present invention may further provide a "linker" peptide. Preferably the linker peptide is linked to the amino acid sequence of the proteolytic cleavage site. The linker peptide may be provided at the C terminal or N terminal end of the amino acid sequence encoding the proteolytic cleavage site. Preferably, the linker peptide is continuous with the amino acid sequence of the proteolytic cleavage site. The linker peptide may comprise the amino acid sequence encoded by nucleotides 831-843 and/or 862-873 of Figure 1 or nucleotides 553-564 and/or 586-597 of Figure 2 or a sequence of nucleotides which has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% identity, using the default parameters of the BLAST computer program provided by HGMP, thereto.

The term "linker peptide" is intended to define any sequence of amino acid residues which preferably provide a hydrophilic region when contained in an expressed protein. Such a hydrophilic region may facilitate cleavage by an enzyme at the proteolytic cleavage site.

The term "latency" as used herein, may relate to a shielding effect which may hinder interaction between the fusion protein and other molecules in the cell surface. Alternatively the term latency may be used to describe a reduction in the activity (up to and including ablation of activity) of a molecule/agent associated with the fusion protein. The term latency may also relate to a stabilising effect of the fusion protein. The effect may be in full or partial, where a partial effect is sufficient to achieve the latency of the active agent.

The pharmaceutically active agent may include, but is not limited to, a growth factor (eg. TGF β , epidermal growth factor (EGF), platelet derived growth factor (PDGF), nerve growth factor (NGF), colony stimulating factor (CSF), hepatocyte growth factor, insulin-like growth factor, placenta growth factor); differentiation factor; cytokine eg. interleukin, (eg. IL1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20 or IL21, either α

or β), interferon (eg. IFN- α , IFN- β and IFN- γ), tumour necrosis factor (TNF), IFN- γ inducing factor (IGIF), bone morphogenetic protein (BMP); chemokine (eg. MIPs (Macrophage Inflammatory Proteins) e.g. MIP1 α and MIP1 β ; MCPs (Monocyte Chemotactic Proteins) e.g. MCP1, 2 or 3; RANTES (regulated upon activation normal T-cell expressed and secreted)); trophic factors; cytokine inhibitors; cytokine receptors; free-radical scavenging enzymes e.g. superoxide dismutase or catalase; pro-drug converting enzymes (e.g. angiotensin converting enzyme, deaminases, dehydrogenases, reductases, kinases and phosphatases); peptide mimetics; protease inhibitors; tissue inhibitor of metalloproteinase sub classes (TIMPS) and serpins (inhibitors of serine proteases). Preferably, the pharmaceutically active agent will be derived from the species to be treated e.g. human origin for the treatment of humans. Preferably, the pharmaceutically active agent is IFN β .

As used herein "peptide mimetics" includes, but is not limited to, agents having a desired peptide backbone conformation embedded into a non-peptide skeleton which holds the peptide in a particular conformation. Peptide mimetics, which do not have some of the drawbacks of peptides, are of interest in those cases where peptides are not suitable in medicine.

Peptide mimetics may comprise a peptide backbone which is of the L or D conformation. Examples of peptide mimetics include melanocortin, adrenocorticotrophin hormone (ACTH) and other peptide mimetic agents which play a role in the central nervous system, endocrine system in signal transduction and in infection and immunity.

The pharmaceutically active agent may comprise a chemical compound such as a chemotherapeutic agent or other synthetic drug. Alternatively, the pharmaceutically active agent may comprise a peptide nucleic acid (PNA) sequence e.g. a poly-lysine sequence which binds to nucleic acids and permeabilises lipid bilayers (Wyman et al., *Biological Chemistry*, **379**, 1045-1052 (1998)) or a KALA peptide which facilitates transfer through lipid bilayers (Wyman et al., *Biochemistry*, **36**, 3008-3017 (1997)).

The term "associating with" in the context of the present invention is intended to include all means of association including, but not limited to, chemical cross-linking or peptide bond linkage.

In an alternative embodiment, the invention further provides the fusion protein of the present invention optionally in association with latent TGF β binding protein (LTBP). Typically, the fusion protein is covalently linked to LTBP to form a complex. Preferably, the association is mediated by disulphide bond(s) between Cys No. 33 of LAP and the third 8 Cys residue of LTBP. The LTBP associated with the fusion protein may include, but is not limited to, LTBP 1, 2, 3 or 4 (Kanzaki et al., *Cell*, **61**, 1051-1061 (1990); Tsuji et al., *Proc. Natl. Acad. Sci. USA*, **87**, 8835-8839 (1990); Moren et al., *J. Biol. Chem.* **269**, 32469-32478 (1994); Yin et al., *J. Biol. Chem.* **270**, 10147-10160 (1995); Gibson et al., *Mol. Cell. Biol.* **15**, 6932-6942 (1995); Saharinen et al., *J. Biol. Chem.* **273**, 18459-18469 (1998)), or fragments of LTBP such as that containing the third 8 Cys repeat, or homologues having a sequence of amino acids or nucleotides which has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% identity, using the default parameters of the BLAST computer program provided by HGMP, to that of LTBP.

Cleavage of LTBP may release the fusion protein from the LTBP complex. Enzymes which may cleave LTBP in this manner include, but are not limited to, thrombospondin (Schultz et al., *The Journal of Biological Chemistry*, **269**, 26783-26788 (1994); Crawford et al., *Cell*, **93**, 1159-1170 (1998)), transglutaminase (Nunes et al., *J. Cell. Biol.* **136**, 1151-1163 (1997); Kojima et al., *The Journal of Cell Biology*, **121**, 439-448 (1993)) MMP9 and MMP2 (Yu and Stamenkovic, *Genes and Dev*, **14**, 163-176 (2000)).

A third aspect of the invention provides a nucleic acid construct comprising a first nucleic acid sequence encoding a pharmaceutically active agent, a second nucleic acid sequence encoding a LAP, wherein a nucleic acid sequence encoding a proteolytic cleavage site is provided between the first and second nucleic acid sequences.

The term "nucleic acid construct" generally refers to any length of nucleic acid which may be DNA, cDNA or RNA such as mRNA obtained by cloning or produced by chemical synthesis. The DNA may be single or double stranded. Single stranded DNA may be the coding sense strand, or it may be the non-coding or anti-sense strand. For therapeutic use, the nucleic acid construct is preferably in a form capable of being expressed in the subject to be treated.

Preferably, the first nucleic acid sequence encodes the protein IFN β . The first nucleic acid sequence may comprise the sequence of nucleotides from 874-1376 of Figure 1 or nucleotides 598-1352 of Figure 2, or a sequence which is substantially homologous thereto. In one embodiment of the invention, the first nucleic acid sequence encodes IFN β from a mouse or a human .

The nucleic acid construct of the third aspect of the invention may be in the form of a vector, for example, an expression vector, and may include, among others, chromosomal, episomal and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova-viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. Generally, any vector suitable to maintain, propagate or express nucleic acid to express a polypeptide in a host, may be used for expression in this regard.

Preferably, the nucleic acid construct is LAP-huIFN β or huIFN β -LAP as defined herein in Example 4. Alternatively, the nucleic acid construct may be LAP-mIFN β as shown in Figure 1 and schematically in Figure 5 or mIFN β -LAP as shown in Figure 2 and schematically in Figure 5.

The invention further provides a protein encoded by the nucleic acid construct of the third aspect of the invention optionally in association with latent TGF β binding protein (LTBP) described herein. Typically, the protein encoded by the nucleic acid

construct is covalently linked to LTBP to form a complex. Preferably, the association is mediated by disulphide bond(s) between Cys No. 33 of LAP and the third 8 Cys residue of LTBP.

The nucleic acid construct of the third aspect of the invention preferably includes a promoter or other regulatory sequence which controls expression of the nucleic acid. Promoters and other regulatory sequences which control expression of a nucleic acid have been identified and are known in the art. The person skilled in the art will note that it may not be necessary to utilise the whole promoter or other regulatory sequence. Only the minimum essential regulatory element may be required and, in fact, such elements can be used to construct chimeric sequences or other promoters. The essential requirement is, of course, to retain the tissue and/or temporal specificity. The promoter may be any suitable known promoter, for example, the human cytomegalovirus (CMV) promoter, the CMV immediate early promoter, the HSV thymidinekinase, the early and late SV40 promoters or the promoters of retroviral LTRs, such as those of the Rous Sarcoma virus (RSV) and metallothionine promoters such as the mouse metallothionine-I promoter. The promoter may comprise the minimum comprised for promoter activity (such as a TATA elements without enhancer elements) for example, the minimum sequence of the CMV promoter.

Preferably, the promoter is contiguous to the first and/or second nucleic acid sequence.

As stated herein, the nucleic acid construct of the third aspect of the invention may be in the form of a vector. Vectors frequently include one or more expression markers which enable selection of cells transfected (or transformed) with them, and preferably, to enable a selection of cells containing vectors incorporating heterologous DNA. A suitable start and stop signal will generally be present.

One embodiment of the invention relates to a cell comprising the nucleic acid construct of the third aspect of the invention. The cell may be termed a "host" cell, which is useful for the manipulation of the nucleic acid, including cloning. Alternatively, the cell may be a cell in which to obtain expression of the nucleic acid. Representative examples of appropriate host cells for expression of the nucleic acid

construct of the invention include virus packaging cells which allow encapsulation of the nucleic acid into a viral vector; bacterial cells, such as *Streptococci*, *Staphylococci*, *E.coli*, *Streptomyces* and *Bacillus Subtilis*; single cells, such as yeast cells, for example, *Saccharomyces Cerevisiae*, and *Aspergillus* cells; insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells, animal cells such as CHO, COS, C127, 3T3, PHK.293, and Bowes Melanoma cells and other suitable human cells; and plant cells e.g. *Arabidopsis thaliana*.

Induction of an expression vector into the host cell can be affected by calcium phosphate transfection, DEAE-dextran mediated transfection, microinjection, cationic – lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Sambrook et al, Molecular Cloning, a Laboratory Manual, Second Edition, Coldspring Harbor Laboratory Press, Coldspring Harbor, N.Y. (1989).

Mature proteins can be expressed in host cells, including mammalian cells such as CHO cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can be employed to produce such proteins using RNAs derived from the nucleic acid construct of the third aspect of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al, Molecular Cloning, a Laboratory Manual, Second Edition, Coldspring Harbor Laboratory Press, Coldspring Harbor, N.Y. (1989).

Proteins can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, high performance liquid chromatography and lectin chromatography. For therapy, the nucleic acid construct e.g. in the form of a recombinant vector, may be purified by techniques known in the art, such as by means of column chromatography as described in Sambrook et al, Molecular Cloning, a

Laboratory Manual, Second Edition, Coldspring Harbor Laboratory Press, Coldspring Harbor, N.Y. (1989).

In a fourth aspect, the invention provides a method of treatment of a patient such as a mammal, including human, comprising administering to a recipient a therapeutically effective amount of the nucleic acid construct of the third aspect of the invention. Where the nucleic acid construct is used in the therapeutic method of the invention, the construct may be used as part of an expression construct, e.g. in the form of an expression vector such as a plasmid or virus. In such a method, the construct may be administered intravenously, intradermally, intramuscularly, orally or by other routes.

The nucleic acid construct of the third aspect of the invention, and proteins derived therefrom, may be employed alone or in conjunction with other compounds, such as therapeutic compounds, e.g. anti-inflammatory drugs, cytotoxic agents, cytostatic agents or antibiotics. The nucleic acid constructs and proteins useful in the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

As used herein, the term "treatment" includes any regime that can benefit a human or a non-human animal. The treatment of "non-human animals" extends to the treatment of domestic animals, including horses and companion animals (e.g. cats and dogs) and farm/agricultural animals including members of the ovine, caprine, porcine, bovine and equine families. The treatment may be in respect of any existing condition or disorder, or may be prophylactic (preventive treatment). The treatment may be of an inherited or an acquired disease. The treatment may be of an acute or chronic condition. Preferably, the treatment is of a condition/disorder associated with inflammation. The first nucleic acid sequence of the nucleic acid construct of the third aspect of the invention may encode a protein for use in the treatment of the disorder, including, but not limited to osteoarthritis, scleroderma, renal disease, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, atherosclerosis, cancer, or any inflammatory disease.

The nucleic acid construct of the third aspect of the invention may be used therapeutically in the method of the invention by way of gene therapy. Alternatively,

protein encoded by the nucleic acid construct may be directly administered as described herein.

Administration of the nucleic acid construct of the third aspect may be directed to the target site by physical methods. Examples of these include topical administration of the “naked” nucleic acid in the form of a vector in an appropriate vehicle, for example, in solution in a pharmaceutically acceptable excipient, such as phosphate buffered saline, or administration of a vector by physical method such as particle bombardment according to methods known in the art.

Other physical methods for administering the nucleic acid construct or proteins of the third aspect of the invention directly to the recipient include ultrasound, electrical stimulation, electroporation and microseeding. Further methods of administration include oral administration or administration through inhalation.

Particularly preferred is the microseeding mode of delivery which is a system for delivering genetic material into cells *in situ* in a patient. This method is described in US Patent No. 5697901.

The nucleic acid construct according to the third aspect of the invention may also be administered by means of delivery vectors. These include viral delivery vectors, such as adenovirus or retrovirus delivery vectors known in the art.

Other non-viral delivery vectors include lipid delivery vectors, including liposome delivery vectors known in the art.

Administration may also take place via transformed host cells. Such cells include cells harvested from the subject, into which the nucleic acid construct is transferred by gene transfer methods known in the art. Followed by the growth of the transformed cells in culture and grafting to the subject.

As used herein the term “gene therapy” refers to the introduction of genes by recombinant genetic engineering of body cells (somatic gene therapy) or of cells of the germ line (germ-line therapy) for the benefit of the patient. Furthermore, gene therapy can be divided into *ex vivo* and *in vivo* techniques. *Ex vivo* gene therapy

relates to the removal of body cells from a patient, treatment of the removed cells with a vector ie, a recombinant vector, and subsequent return of the treated cells to the patient. *In vivo* gene therapy relates to the direct administration of the recombinant gene vector by, for example, intravenous or intravascular means.

Preferably the method of gene therapy of the present invention is carried out *ex vivo*.

Preferably in gene therapy, the expression vector of the present invention is administered such that it is expressed in the subject to be treated. Thus for human gene therapy, the promoter is preferably a human promoter from a human gene, or from a gene which is typically expressed in humans, such as the promoter from human CMV.

For gene therapy, the present invention may provide a method for manipulating the somatic cells of human and non-human mammals.

The present invention also provides a gene therapy method which may involve the manipulation of the germ line cells of a non-human mammal.

The present invention therefore provides a method for providing a human with a therapeutic protein comprising introducing mammalian cells into a human, the human cells having been treated *in vitro* to insert therein a nucleic acid construct according to the third aspect of the invention.

Each of the individual steps of the *ex vivo* somatic gene therapy method are also covered by the present invention. For example, the step of manipulating the cells removed from a patient with the nucleic acid construct of the third aspect of the invention in an appropriate vector. As used herein, the term "manipulated cells" covers cells transfected with a recombinant vector.

Also contemplated is the use of the transfected cells in the manufacture of a medicament for the treatment of an inflammatory disorder.

A fifth aspect of the invention provides a nucleic acid construct, or protein encoded thereby, according to the third aspect of the invention for use in medicine, preferably for use in gene therapy.

The present invention may also find application in veterinary medicine for treatment/prophylaxis of domestic animals including horses and companion animals (e.g. cats and dogs) and farm animals which may include members of the ovine, porcine, caprine, bovine and equine families.

A sixth aspect of the invention provides for the use of the nucleic acid construct according to the third aspect of the invention in the manufacture of a medicament for the treatment of an inflammatory disorder. In this context, the inflammatory disorder may include any one or more of the inflammation associated conditions discussed above.

The present invention also relates to compositions comprising the nucleic acid construct or proteins of the third aspect of the invention. Therefore, the nucleic acid construct of the present invention may be employed in combination with the pharmaceutically acceptable carrier or carriers. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, liposomes, water, glycerol, ethanol and combinations thereof.

The pharmaceutical compositions may be administered in any effective, convenient manner effective for treating a patient's disease including, for instance, administration by oral, topical, intravenous, intramuscular, intranasal, or intradermal routes among others. In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

For administration to mammals, and particularly humans, it is expected that the daily dosage of the active agent will be from 0.01mg/kg body weight, typically around 1mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual which will be dependant on factors including the age, weight, sex and response of the individual. The above dosages are exemplary of the

average case. There can, of course, be instances where higher or lower dosages are merited, and such are within the scope of this invention

A seventh aspect of the invention provides a fusion protein comprising a LAP and a proteolytic cleavage site wherein the fusion protein is associated with a pharmaceutically active agent.

The invention further provides a nucleic acid construct encoding the fusion protein of the seventh aspect of the invention. The nucleic acid construct preferably comprises a nucleic acid sequence encoding a LAP adjacent a nucleic acid sequence encoding a proteolytic cleavage site. Preferably, the nucleic acid sequence encoding a LAP is suitably operably linked to a nucleic acid sequence encoding a proteolytic cleavage site. The nucleic acid construct encoding the fusion protein may comprise nucleotides 1-861 of Figure 1 or nucleotides 585-1352 of Figure 2 or a sequence of nucleotides which has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% identity, using the default parameters of the BLAST computer program provided by HGMP, thereto.

The invention further provides the fusion protein of the seventh aspect of the invention optionally in association with latent TGF β binding protein (LTBP) described herein.

The fusion protein of the seventh aspect of the invention may be associated with the pharmaceutically active agent by means of a peptide bond linkage. Alternatively, the fusion protein may be associated with the pharmaceutically active agent by means of a chemical linkage e.g. by cross-linking the fusion protein to a chemical compound such as a chemotherapeutic agent, synthetic drug or PNA.

Preferably, the pharmaceutically active agent is linked to the C-terminal end of the amino acid sequence of the proteolytic cleavage site in the fusion protein of the seventh aspect of the invention. More preferably, the pharmaceutically active agent is continuous with the C-terminal residue of the amino acid sequence of the proteolytic cleavage site.

An eighth aspect of the invention provides a process for preparing the fusion protein, and associated pharmaceutically active agent, of the seventh aspect of the invention comprising production of the fusion protein recombinantly by expression in a host cell, purification of the expressed fusion protein and association of the pharmaceutically active agent to the purified fusion protein by means of peptide bond linkage or chemical cross linking.

In a ninth aspect, the invention provides a method of treatment of a patient such as a mammal, including human, comprising administering to a recipient a therapeutically effective amount of the fusion protein, and associated pharmaceutically active agent, of the seventh aspect of the invention. In such a method, the fusion protein and associated pharmaceutically active agent may be administered intravenously, intradermally, intramuscularly, orally or by other routes.

The fusion protein, and associated pharmaceutically active agent of the seventh aspect of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds, e.g anti-inflammatory drugs, cytotoxic agents, cytostatic agents or antibiotics.

Preferably, the fusion protein and associated pharmaceutically active agent of the seventh aspect of the invention are directly administered to a patient as described herein.

A tenth aspect of the invention provides a fusion protein and associated pharmaceutically active agent according to the seventh aspect of the invention for use in medicine.

An eleventh aspect of the invention provides for the use of the fusion protein and associated pharmaceutically active agent according to the seventh aspect of the invention in the manufacture of a medicament for the treatment of an inflammatory disorder. In this context, the inflammatory disorder may include any one or more of the inflammation associated conditions discussed herein.

The present invention also relates to compositions comprising the fusion protein and associated pharmaceutically active agent of the seventh aspect of the invention. Therefore, the fusion protein and associated pharmaceutically active agent may be employed in combination with the pharmaceutically acceptable carrier or carriers. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, liposomes, water, glycerol, polyethylene glycol, ethanol and combinations thereof.

The pharmaceutical compositions may be administered in any effective, convenient manner effective for treating a patient's disease including, for instance, administration by oral, topical, intravenous, intramuscular, intranasal, or intradermal routes among others. In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

The invention also provides a kit of parts comprising a nucleic acid construct of the third aspect of the invention, or a fusion protein and associated pharmaceutically active agent according to the seventh aspect of the invention, and an administration vehicle including, but not limited to, tablets for oral administration, inhalers for lung administration and injectable solutions for intravenous administration.

A preferred embodiment of the present invention provides a method of providing latency to a pharmaceutically active agent which is a cytokine, preferably interferon, the method comprising constructing a fusion protein having a latency associated peptide, preferably from TGF β , associated with a proteolytic cleavage site, preferably a matrix metalloproteinase (MMP) cleavage site, and the pharmaceutically active agent. Preferably, the pharmaceutically active agent is followed by the proteolytic cleavage site and the LAP as follows: active agent - cleavage site - LAP.

All preferred features of the second and subsequent aspects of the invention are as for the first aspect *mutatis mutandis*.

The present invention will now be described by way of example only with reference to the accompanying figures wherein:

- FIGURE 1 shows nucleotide (A) and corresponding amino acid (B) sequence of the LAP-mIFN β construct. The boxed sequence corresponds to the sequence of the MMP cleavage site including linker sequence;
- FIGURE 2 shows nucleotide (A) and corresponding amino acid (B) sequence of the mIFN β -LAP construct. The boxed sequence corresponds to the sequence of the MMP cleavage site including linker sequence;
- FIGURE 3 shows amino acid sequences of the precursor domain of TGF β 1, 2 and 3 (human, Hu), TGF β 4 (chicken, Ck), TGF β (frog, Fg). Arrows indicate the position of the proteolytic processing resulting in cleavage of the signal peptide of TGF β 1 and of the mature TGF β s. N-linked glycosylation sites are underlined, as is the integrin cellular recognition sequence (Roberts and Sporn, Peptide Growth Factors and their Receptors: Sporn, MB and Roberts, AB, Springer-Verlag, Chapter 8, 422 (1996));
- FIGURE 4 shows the sequences of protein cleavage sites of matrix metalloproteinases (MMPs) (Nagase and Fields, Biopolymers, **40**, 399-416 (1996));
- FIGURE 5 shows schematic representation of the fusion proteins used in this study and their putative folding. (A) Primary structure of recombinant latent proteins. The linear sequence arrangement of the LAP, MMP and mIFN β constituents in the two configurations used in this study, LAP- mIFN β and mIFN β -LAP, is shown. The box at the amino terminal end of LAP- mIFN β and mIFN β -LAP depicts the native signal sequence peptide for secretion of either TGF β or mIFN β respectively. (B) Putative folding and interactions with LTBP of latent cytokine. In LTBP, the EGF like repeats are shown as small squares, the cysteine-rich repeats and hybrid domain as circles, and the 'hinge region' which is sensitive to proteolytic cleavage is shown as a solid black line. Disulphide bonds are shown as solid grey lines;

FIGURE 6 shows detection of recombinant fusion proteins in supernatants of CHO cells. Non denaturing SDS-PAGE of supernatants from CHO cells (lane 1), LAP-mIFN β transfected (lane 2) and mIFN β -LAP (lane 3). Position of the double bands of newly expressed fusion proteins are marked by a double arrow. Position of the molecular weight markers (M.W.) in kDa is shown;

FIGURE 7 shows immunoprecipitation of CHO cell supernatants with anti-LAP antibody and cleavage with MMP1 and MMP3. LAP-mIFN β (lanes 1,3 and 5) and mIFN β -LAP (lanes 2, 4 and 6). Untreated controls (lanes 1 and 2), treated with MMP3 (lanes 3 and 4), treated with MMP1 (lanes 5 and 6). SDS PAGE was performed under denaturing conditions. The positions of LTBP and fusion proteins, are indicated by arrows. The arrows marked with an asterisk (*) indicates the presence of MMP cleavage products. Position of the molecular weight markers (M.W.) in kDa is shown;

FIGURE 8 shows immunoprecipitation of MTX-selected CHO cell supernatants with anti-LAP and anti-IFN β antibodies and cleavage with MMP1, MMP3 and synovial fluid from rheumatoid arthritis patients. (A). LAP-mIFN β and (B). mIFN β -LAP. Untreated supernatants (lanes 1 and 5), MMP1 treated (lanes 2 and 6), MMP3 treated (lanes 3 and 7) and rheumatoid arthritis synovial fluid treated (lanes 4 and 8). Immunoprecipitated with anti-LAP (lanes 1-4) and anti-IFN β monoclonal antibody (lanes 5-8). The positions of LTBP and fusion proteins are indicated by arrows. The arrows marked with an asterisk (*) indicates the presence of MMP cleavage products;

FIGURE 9 shows kinetics of IFN activity following incubation in medium alone or with rheumatoid arthritis synovial fluid. A. LAP-mIFN β ; Panel B. mIFN β -LAP.

FIGURE 10 shows the inhibition of collagen-induced arthritis by DNA injection with LAP-IFN β . Panel A shows hind paw swelling and Panel B shows clinical score development from time of boost with collagen type II.

FIGURE 11 shows the predicted nucleotide (A) and corresponding amino acid (B) sequence of the huIFN β -LAP construct.

FIGURE 12 shows the predicted nucleotide (A) and corresponding amino acid (B) sequence of the LAP-huIFN β construct.

The invention is now described with reference to the following non-limiting examples;

Example 1-Construction of hLAP-mIFN β , mIFN β -hLAP and pLAP-mIFN β

Fusion Proteins

Methods

Cloning of GS-MMP-GS linker into EcoR1-Not1 sites of pcDNA3

A vector was constructed by inserting the GS-MMP-GS linker into EcoR1-Not1 cleaved pcDNA3. pcDNA3 is an expression vector (from Invitrogen) which comprises the human cytomegalovirus immediate early promoter and enhancer, together with RNA processing signals allowing transcription.

Double stranded deoxyoligonucleotide coding for the sequence GLY GLY GLY GLY SER PRO LEU GLY LEU TRP ALA GLY GLY GLY SER was designed as follows:

Sense oligo:

5'AATTCGGGGGAGGCGGATCCCCGCTCGGGCTTTGGGCGGGAGGGGGC
TCAGC 3'

Antisense oligo:

5' GGCCGCTGAGCCCCCTCCCGCCCAAAGCCCGAGCGGGGATCCGCCTCC
CCCG 3'

Synthetic deoxyoligonucleotides were purchased from Life Technologies Ltd. (Paisley, UK). Annealed deoxyoligonucleotides were cloned into EcoR1-Not1 cleaved pcDNA3 (Invitrogen, Groningen, The Netherlands). The recombinant clone

lost its EcoRV site and gained an additional BamHI site. Plasmid clones were assessed by Southern blot hybridization with end labeled oligos. The clone was referred to as GS-MMP-GS. Restriction enzymes and DNA modifying enzymes were obtained from New England Biolabs, Hitchin, UK.

Construction of LAP (TGF β) at NH₂ end followed by GS-MMP-GS and mature IFN β

A vector comprising LAP (TGF β) followed by GS-MMP-GS and mature IFN β was constructed as follows:

LAP from TGF β as a 5' unit (with signal peptide) with HindIII and EcoR1 ends was cloned by PCR from plasmid TGF β -Babe neo (Chernajovsky et al., Gene Ther. 4, 553-559 (1997)). The following primers were used:

Sense Primer 5' CCAAGCTTATGCCGCCCTCCGGGCTGCGG 3'

Antisense primer 5' CCGAATTCGCTTTGCAGATGCTGGGCCCT 3'

After PCR, the product was phenol extracted, ends filled-in with Klenow and digested with HindIII and EcoR1. The 820 bp product was cloned into GS-MMP-GS plasmid cut with the same enzymes. The clone was referred to as TGF β -GS-MMP-GS linker. Mature mIFN β (from mouse) with 5' NotI and 3' XbaI sites was synthesized by PCR from clone Aphrodite (Triantaphyllopoulos et al., Gene Ther. 5, 253-263 (1998)) using the following primers:

Sense primer 5' CGCGGCCGCAATCAACTATAAGCAGCTCCAG 3'

Antisense primer 5' GGTCTAGATCAGTTTTGGAAGTTTCTGGTAAG 3'

After PCR, the fragment was phenol extracted, ends filled-in with Klenow and digested with NotI and XbaI. The LAP-mIFN β clone was obtained by cloning the fragment into the NotI and XbaI sites of TGF β -GS-MMP-GS linker plasmid.

The nucleotide and amino acid sequence of the LAP-mIFN β insert is shown in Figure 1.

Construction of mIFN β at NH₂ end followed by GS-MMP-GS and mature LAP (TGF β)

A vector comprising mature mIFN β followed by GS-MMP-GS and LAP (TGF β) was constructed as follows:

Pre-IFN β with signal peptide and without stop codon was synthesised by PCR as above using the following primers:

Sense primer 5' CCAAGCTTATGAACAACAGGTGGATCCTC 3'

Antisense primer 5' CCGAATTCGTTTTGGAAGTTTCTGGTAAG 3'

After PCR synthesis, phenol extraction, filling-in with Klenow fragment of DNA polymerase, the DNA product was digested with HindIII and EcoRI and cloned into plasmid pCDNA3 GS-MMP-GS in same sites. The clone was referred to as IFN β -GS-MMP-GS linker. Mature LAP (TGF β) with stop codon was synthesised by PCR as above using the following primers:

Sense primer 5' CGCGGCCCGCACTATCCACCTGCAAGACTATC 3'

Antisense primer 5' GGTCTAGATCAGCTTTGCAGATGCTGGGCCCT 3'

After PCR and phenol extraction, the ends were filled-in with Klenow and digested with NotI and XbaI. The mIFN β -LAP clone was obtained by cloning the PCR fragment into the same sites of plasmid IFN β -GS-MMP-GS. The nucleotide and amino acid sequence of the mIFN β -LAP insert is shown in Figure 2.

Cloning of porcine LAP in front of mIFN β

Mutated porcine cDNA, mutated at Cys to Ser (223/225), as plasmid pPK14 (Sanderson et al., Proc. Natl. Acad. Sci. USA, **92**, 2572-2576 (1995), was kindly provided by P.J. Wirth, NIH, Bethesda, Maryland. Cloning of porcine LAP was carried out by PCR, using the following set of primers:

Sense primer starting at signal peptide was 5' CGCCCATGGCGCCTTCGGGGCCT 3'. This primer has a modified sequence around the initiator ATG to create a NcoI site.

Antisense primer 5' CCGAATTCGCTGTGCAGGTGCTGGGCCCT 3'

Following PCR synthesis, the PCR product was end-filled with Klenow-DNA polymerase, cut with EcoRI, cloned into LAP-mIFN β plasmid cut with HindIII (filled-in) and then cut with EcoRI (exchanging human LAP). The construct was named PorcLap-mIFN β .

Results

Structural considerations

In order to develop a latent-cytokine using the LAP domain of TGF β fusion proteins in two conformations, one containing LAP at the amino terminal end of mouse IFN β (see Figure 1) and another at its COOH end (see Figure 2), were constructed.

To avoid processing of the LAP-mIFN β protein at Arg 278 of LAP, LAP spanning amino acids Met 1-Ser 273 was cloned. This sequence was followed by a flexible linker (GGGGS), a putative MMP9 (Peng et al., Human Gene Therapy, **8**, 729-738 (1997); Ye et al., Biochemistry, **34**, 4702-4708 (1995)) or putative MMP1 (Nagase and Fields, Biopolymers, **40**, 399-416 (1996)) cleavage site (PLGLWA) and another flexible portion (GGGGSAAA) followed by mature mIFN β (starting at amino acid Ile-22). Embedding the MMP cleavage site in a hydrophilic area should facilitate access to enzymatic attack. The core of the cleavage site (PLGL) has been shown to be cleaved as a peptide by MMP2 and in a different version (PLGI) also by MMP3, MMP7 and MMP8 (Nagase and Fields, Biopolymers, **40**, 399-416 (1996)).

The IFN β -LAP molecule consisted of the precursor mIFN β sequence where its stop codon was mutated to allow read through the flexible linker and MMP site followed by the mature sequence of LAP (from Leu-29 to Ser-273).

The unprocessed LAP-mIFN β and mIFN β -LAP fusion proteins have an expected molecular weight of 52,375 and 51,768 Daltons respectively. The primary sequence of these fusion proteins contains four possible N-glycosylation sites. A schematic representation of the primary structure and putative folding of these proteins and their possible interaction with LTBP is shown in Fig. 5. On the right panel of Figure 5B the folding of LAP-mIFN β is shown resembling the folding of native TGF β . Near the amino terminal end (N) of the LAP-mIFN β , Cys 33 interacts with the third 8-cysteine-rich repeat of LTBP, whilst Cys 224 and 226 are expected to dimerize the protein by intermolecular disulphide bonds (Saharinen et al., Cytokine and Growth Factors, **10**, 99-117 (1999)). On the left panel of Figure 5B, the structure of mIFN β -LAP is shown. Cys 33 is now located behind the MMP cleavage site and Cys 224 and 226 are closer to the carboxy (C) end of the protein.

Example 2 - Cell transfection studies

Methods

Transfection into DHFR-deficient chinese hamster ovary (CHO) cells

Dihydrofolate reductase (DHFR) -deficient CHO cells were maintained in HAM-F12 medium (Life Technologies Ltd., Paisley, UK) with 10% fetal bovine serum (FBS) (Life Technologies Ltd.), penicillin/streptomycin and glutamine.

pcDNA3 plasmids (20 µg) expressing LAP-mIFN β or mIFN β -LAP were each linearized with PvuI and ligated separately with PvuI cut pSV₂DHFR (1 µg) (Chernajovsky et al., DNA, 3, 297-308 (1984)). After phenol extraction, the plasmids were ligated in 300 µl with T4 DNA ligase at 16°C for 3 days. The DNA was precipitated in 0.4 M NH₄ acetate and resuspended in water to be added as 1 ml calcium phosphate co-precipitate on 0.5 x 10⁶ CHO cells on 9 cm plates seeded 24 hrs earlier. 4 hrs later, the cells were treated with 10% glycerol in HAM-F12 without FBS, washed in FBS-free media and left to recover for 48 hrs. Transfected cells were trypsinized and split into six 9 cm plates. Selection was carried out in Alpha-DMEM medium without nucleosides (PAA Laboratories, Linz, Austria), 10% dialyzed FBS (PAA Laboratories) and 1 mg/ml G418 (Geneticin, from Life Technologies Ltd.). Selection media was changed twice a week. Cell clones appeared 2-3 weeks later and were maintained as a population (Chernajovsky et al., DNA, 3, 297-308 (1984)).

For gene amplification, cells were selected additionally with methotrexate (MTX) (Sigma, Poole, UK) at 50 nM (LAP-mIFN β) or 12.5 nM (mIFN β -LAP) respectively. Cell clones were isolated by ring cloning and expanded in selection media.

IFN β biological assay

Mouse IFN β biological activity was assessed by inhibition of the cytopathic effect of EMC virus (kindly provided by I. Kerr, Imperial Cancer Research Fund, London) infection in mouse LTK⁻ cells using doubling dilutions of cell supernatants as described (Triantaphyllopoulos et al., Gene Ther. 5, 253-263 (1998)). Where indicated, serum-free CHO supernatants were concentrated by centrifugation using Vivaspin filters (Sartorius, Goettingen, Germany) with a cut off of 30,000 kDa.

Metabolic labelling of CHO cells

Confluent plates of permanently transfected cells or non-transfected CHO cells were washed with cysteine-methionine free medium (Life Technologies Ltd.) containing 10% dialyzed FBS and supplemented with thymidine, glutamine, penicillin/streptomycin and 150 µg/ml L-proline. Labelling was either overnight or for 48 hrs in the presence of ³⁵S-methionine-cysteine mix (Amersham-Pharmacia Biotech, Bucks, UK) at 1Ci/mmol using 250 mCi/plate in 5 ml media.

At the end of the labelling period, supernatants were collected, cell debris spun down and clear supernatants supplemented where indicated with serine-protease inhibitors (SPI) (pepstatin-A at 10 µg/ml, aprotinin at 1 µg/ml, chymostatin at 10 µg/ml, leupeptin at 10 µg/ml and AEBSF (4-(2-aminoethyl)benzene sulphonyl-fluoride, HCl) at 200 µM (all from Calbiochem, Beeston, UK). These supernatants were frozen at -70°C until used for immunoprecipitation studies.

Immunoprecipitation

Supernatants from metabolically labelled cells were pre-cleared with (400 µl) Protein-G-Sepharose (Amersham Pharmacia Biotech) equilibrated in PBS with 0.1% NP40 (50% beads/vol) (BDH, Poole, UK). Supernatants containing 25x10⁶ cpm of trichloroacetic acid (TCA) (Sigma) total precipitated protein were used (approximately 5-7 ml of cell supernatants). After end-over-end mixing for 4 hrs at 4°C, protein-G Sepharose was removed by centrifugation (2000 RPM, 5 min). The cleared supernatant was incubated with either goat-anti-human-LAP antibody (R&D Systems, Oxon, UK at 0.9 µg/ml), or monoclonal rat-anti-mIFNβ (7F-D3, AMS, Abingdon, UK; at a dilution of 1/250) for 3-4 hrs at 4°C.

The antigen-antibody complexes were then bound to Protein-G-Sepharose (700 µl of 50% solution) by mixing overnight at 4°C rolling end-over-end. Protein-G-Sepharose beads were washed three times with 5 ml 0.1% NP40 in PBS. Proteins bound to beads were split into fractions of 50 µl beads in small tubes and either directly resuspended in Laemmli-loading buffer or used in MMPs reactions prior to SDS-PAGE in 10% acrylamide gel. Alternatively, supernatants were treated with MMPs and then immunoprecipitated. Gels were fixed for 30 min. in 7% acetic acid and 10%

methanol and treated with 1 M sodium salicylate before drying and exposing to autoradiography with X-ray film. Coloured protein molecular weight markers were from Amersham-Pharmacia Biotech.

Supernatants from MTX selected cells were treated with MMPs or synovial fluid from rheumatoid arthritis patients (RA/SF:1/5) overnight, the reactions stopped with 10 mM EDTA and then immunoprecipitated.

MMP digestion

Recombinants pro-MMP9 (kindly provided by R. Fridman, Wayne University, Detroit) or active MMP1 and MMP3 (kindly provided by H. Nagase, Kennedy Institute of Rheumatology, London) were incubated overnight at 37°C with immunoprecipitated supernatants from CHO cells in 20mM TrisHCl pH 7.4, 5mM CaCl₂, 140 mM NaCl and 0.1% Brij 35 (all from Sigma) in 50 µl at 1 µg/ml or were directly added to cell supernatants (at 4 µg/ ml). Aminophenylmercuric acetate (APMA) (Sigma) at 10µM was used in certain experiments to activate pro-MMP9 overnight at 37 °C (Ogata et al., J. Biol. Chem. **270**, 18506-18511 (1995)).

Results

TABLE 1-Biological assay of mIFN β

Sample	Antiviral activity (U/ml)
Non transfected	0
mIFN β -LAP	210
LAP-mIFN β	0

Mean value of triplicate assay

LAP-mIFN β and mIFN β -LAP recombinant proteins were expressed in dihydrofolate reductase deficient chinese hamster ovary (DHFR⁻ CHO) cells (clone CHO-K1) after permanent co-transfection of linearized plasmids with the DHFR plasmid (pSV₂DHFR) (Chernajovsky et al., DNA, **3**, 297-308 (1984)) and selection both in G418 and dialyzed serum.

As shown in Table 1, mIFN β -LAP was secreted having a low residual biological activity whilst LAP-mIFN β was completely “latent” or inactive. The level of protein expression was similar as confirmed by western blotting with an anti-LAP antibody (not shown).

Biochemical characterization of recombinant proteins

Secreted proteins from permanently transfected cells were metabolically labeled with ³⁵S-methionine and cysteine. Both LAP-mIFN β and mIFN β -LAP labeled proteins showed two major bands above 97 kDa in non-reducing conditions that were not seen in supernatants from CHO non-transfected cells (Fig. 6).

Upon immunoprecipitation with anti-LAP antibody, LAP-mIFN β and mIFN β -LAP supernatants showed three bands one at 57 kDa another at 135 kDa and another minor component at around 75 kDa in reducing conditions Fig 7. The 135 kDa protein is probably the CHO-derived (LTBP) which is di-sulphide linked to LAP (Saharinen et al., Cytokine and Growth Factors, 10, 99-117 (1999)).

The minor 75 kDa component (Fig. 7 lanes 1, 3 and 5) becomes the major component recognised by anti-LAP antibody upon gene amplification with MTX (Fig 8A, lanes 1-4). Interestingly, the monoclonal anti-mIFN β antibody does not seem to recognize the 75 kDa glycosylated product (Fig. 8A and 7, lanes 5-8) and the anti-LAP poorly recognizes it in the mIFN β -LAP configuration (Fig. 8A, lanes 5-8) of the protein indicating that the fusion proteins have different conformations. Similar results were obtained when the immunoprecipitated material was treated enzymatically (with MMP1 or MMP3) and then separated on SDS-PAGE. The difference in conformation may explain the different sensitivity of these proteins to different MMPs (see below) and their degree of latency.

The predicted molecular weight of the secreted recombinant proteins is 49,376 Da for both LAP-mIFN β and mIFN β -LAP. The increased molecular weight determined, may be due to glycosylation of these proteins. Incubation of immunoprecipitated proteins with N-glycosidase F, yields two major proteins of molecular weights 70kDa and 51kDa which correspond to LTBP and fusion protein respectively (not shown)

MMP cleavage of recombinant proteins

Immunoprecipitated complexes were treated overnight with single MMPs or their combination. As shown in Fig. 7, pro-MMP9 or MMP1 did not cleave very efficiently the 57 kDa recombinant product. MMP1 was capable of cleaving the glycosylated form of the fusion protein (Fig. 7, lanes 3 and 4; Fig. 8A, lane 2) whilst MMP3 was capable on its own to digest it into several discreet bands Fig. 7 lanes 5 and 6; Fig 8A and 8B, lanes 3 and 7).

The LTBP band was also cleaved by MMP3 (Fig. 7, lane 3 and 4 and Fig. 8B, lanes 3 and 7) giving rise to a 78 kDa product. Two of the digested products (MW 36kDa and 20kDa) correspond to the expected LAP and IFN β polypeptide fragments respectively.

The specificity shown in these *in vitro* experiments may not fully reflect the antiviral activity measured in cell supernatants following MMP treatment. Cell supernatants were already activated to a certain extent indicating that other proteolytic enzymes present in the supernatant may activate the latent-cytokine moiety. Increased proteolysis of the fusion polypeptides after immunoprecipitation using a combination of recombinant pro-MMP9 with MMP1 or MMP3, or with APMA-activated pro-MMP9 on its own *in vitro* (not shown) was not apparent.

Activation of latent IFN β by MMPs

TABLE 2

mIFN β biological activity (U/ml) from concentrated supernatants treated with MMPs

		pro-MMP9	MMP1	MMP3	pro-MMP9+ MMP1	pro-MMP9 + MMP3
mIFN β -LAP	Exp.1	1,305	1,740	870	3,481	7,740
LAP-mIFN β	Exp.1	163	217	109	435	217
	Exp.2	109	N.D.	N.D.	435	217

Concentrated serum-free supernatants were treated with MMPs as shown.

N.D.= not done

TABLE 3

mIFN β biological activity (U/ml) from non-concentrated supernatants from MTX-amplified CHO- transfected cells.

	TREATMENT							
	none	MMP1	MMP3	pro-MMP9	pro-MMP9 + MMP1	pro-MMP9 + MMP3	RA-S.F.	no SPI.
LAP-mIFN (50nM MTX)	288	6144	9216	288	1536	768	1152	768
mIFN β -LAP (12.5nM MTX)	1536	6144	3072	1536	1536	4608	6144	3072

Supernatants were supplemented with or without (last row) serine protease inhibitors (SPI) and MMPs as indicated. The RA.SF is the same used also in Figure 6.

The non-concentrated supernatant had approximately 210 U/ml of antiviral activity corresponding to about 0.3 ng protein (Iwakura et al., J. Biol. Chem. **253**, 5074-5079 (1978)). Cell supernatants were concentrated 100 fold by centrifugation through porous membranes in order to allow for MMP activity at a higher substrate concentration.

Upon concentration, even the LAP-IFN β supernatant demonstrated antiviral activity without any further treatment (Table 3). This result may be explained by the fact that CHO cells are reported to secrete a variety of proteinases (Goldman et al., Cytotechnology, **23**, 103-111 (1997); Satoh et al., Cytotechnology, **13**, 79-88 (1993)) including MMPs (Masure et al., Eur. J. Biochem. **244**, 21-30 (1997)). Possibly, some natural inhibitors of MMPs (TIMPs) may be removed from the proteinases by this concentration method facilitating their activity.

Supernatants from non-transfected CHO cells had no biological activity even after treatment with MMP's or rheumatoid arthritis synovial fluid (RA-S.F) at 1/5 of final volume (data not shown).

Addition of MMP1 to concentrated supernatants slightly increased the biological activity whilst addition of both MMP1 and pro-MMP9 or MMP3 and pro-MMP9 did the same (see Table 2). Interestingly, treatment of IFN β -LAP with MMP1 and pro-MMP9 lead to a 3-6 fold increase in antiviral activity indicating that further activation of this molecule may be obtained.

Using non-concentrated supernatants from MTX amplified cells, it was demonstrated that both MMP1 and MMP3 can activate LAP-IFN β by 21 and 32 fold respectively (Table 3), and that synovial fluid from rheumatoid arthritis patients can activate it up to 4 fold (Table 3). mIFN β -LAP can also be activated but as previously shown (Table 1) its level of basal activity is high. Fig. 8A and 8B (lanes 4 and 8) show that synovial fluid from rheumatoid arthritis patients can also cleave the fusion proteins to discrete products of 36 kDa and 20kDa corresponding to LAP and IFN β respectively.

As mentioned above, incubation of the supernatants without protease inhibitors yields increased biological activity, indicating that secreted enzymes from the CHO cells may cleave it. The sensitivity of the two fusion proteins to the presence of MMP9 is different showing that mIFN β -LAP may be activated whilst for LAP-IFN β , MMP9 appears inhibitory, perhaps inducing its further degradation by other enzymes present in the CHO cell supernatants.

Activation of latent IFN β with samples from inflamed sites

Fig. 8 and Table 3 showed that synovial fluid from rheumatoid arthritis patients is capable of activating the latent cytokine.

To assess whether long term incubation of the latent cytokine with these samples may lead to its degradation or accumulation into active compound, both LAP-mIFN β and mIFN β -LAP were incubated for up to five days at 37°C in the presence or absence of synovial fluid from rheumatoid arthritis patients and then applied to the IFN

biological assay. Empty symbols are samples incubated in medium with 10% FBS whilst filled symbols are samples incubated with 1/5 of vol/vol of rheumatoid arthritis synovial fluid (RA.SF).

Samples were taken at 24 hrs intervals. Fig. 9 shows that incubation over this extended period resulted in increased activity i.e. activation of the LAP-mIFN β up to 10 fold during the first 24-48 hrs with a steady decrease afterwards. The mIFN β -LAP failed to be activated and only a decrease in its activity was seen. This result clearly indicates that the LAP-IFN β conformation can have potential therapeutic uses.

No activation was seen using mIFN β -LAP. Overall, in both cases the protein activity decreased over time as proteases found in the medium of the cells are capable of degrading the engineered proteins.

To determine whether activation of the latent cytokine could be corroborated by using samples from another pathological inflammatory condition, cerebrospinal fluid from experimental allergic encephalomyelitis monkeys were tested. After overnight incubation, two out of the three samples tested increased the biological activity of the fusion proteins up to four times higher than their parallel serum samples (data not shown), indicating that site-specific activation may be obtainable.

Example 3

In order to assess whether the latency detected with LAP-mIFN β required the formation of a putative closed shell structure bounded by the dimeric disulphide linked LAP, a fusion protein was constructed using the porcine LAP that was mutated in Cys 223 and 225 to Ser.

Methods

Preparation of construct

Porcine LAP was cloned by PCR as set out in Example 1. The primers used were as set out in Example (cloning of porcine LAP). The cloned porcine LAP was mutated in

Cys 223 and 225 to Ser (Sanderson et al., Proc. Natl. Acad. Science, **92**, 2572-2576 (1995)).

Transient transfection into monkey COS-7 cells

20 µg plasmid DNA, PorcLAP-mIFN β and mIFN β -LAP & LAP-mIFN β controls, were transfected by the calcium phosphate co-precipitation method in duplicates to 0.5x10⁶ COS-7 cells seeded in 9 cm plates as described above. The DNA co-precipitate was left on the cells overnight instead of 4 hrs. COS-7 cells were grown in DMEM with antibiotics and 10% FBS. 48hrs after glycerol shock the supernatants were collected for IFN antiviral assay.

Results

The mutated construct PorcLAP-mIFN β was compared to the other constructs for its biological activity in vitro following transient transfection to COS-7 cells. Table 4 shows that PorcLAP-mIFN β was as active as mIFN β -LAP in this assay demonstrating that.

Table 4.

Plasmid	Antiviral activity (U/ml)
LAP-mIFN β	0
PorcLAP-mIFN β	256
mIFN β -LAP	256

Results shown are representative of one of two experiments.

Conclusion

The results show that disulphide bonds at positions 223 and 225 are required for latency of LAP-mIFN β .

Example 4

Cloning and expression of human IFN β -, IL-2- and IL-10-LAP fusion proteins

Construction of human IFN β -MMP-LAP and LAP-MMP-human IFN β will facilitate testing of the expression of these constructs in CHO cell lines and subsequent testing of the activity of the expressed product with some human cell lines *in vitro* and *in vivo*.

Constructs comprising human IL-2 and IL-10 will be expressed and tested as above. Purification of the expressed fusion proteins will utilise a poly His tail as an anchor for purification schemes. Such purification schemes are well known in the art.

Construction of human IFN-LAP and LAP-human IFN fusion proteins

Methods

As with the mouse IFN β gene (see Example 1), the human IFN gene was cloned at the COOH end of the MMP site (after LAP) at the Not1/Xba1 sites giving rise to molecule OM52 (LAP-hu IFN β) using the following primers:

Sense primer

5¹ cgc/g gcc gca ATG AGC TAC AAC TTG CTT GG

Antisense primer

5¹ ggt/ctaga TCA GTT TCG GAG GTA ACC

The PCR product was obtained by PCR of plasmid PSVEIF (Chernajovsky et al. DNA 3, 297-308, (1984)), the PCR product was digested with Not1 and Xba1 and cloned into the plasmid expressing LAP-mIFN beta digested with the same enzymes and from which the mouse gene was removed.

Human pre IFN β was cloned before human LAP giving rise to molecule OM53 (huIFN β -LAP), using the following PCR primers:

Sense primer

5' cca /agc tt ATG ACC AAC AAG TGT C

Anti sense primer

5' ccg/aat tc GTT TCG GAG GTA ACC TG

Plasmid PSVEIF was used as template for the PCR reaction as above and the PCR product was digested with HindIII and EcoR1 and cloned into the same sites of mIFN β -LAP from which the mouse cDNA was removed.

The nucleotide and amino acid sequence of the huIFN β -LAP construct and the LAP-huIFN β constructs are shown in Figures 11 and 12 respectively.

To assess the latency or activity of these molecules, CHO cells were permanently co-transfected with 20 micrograms of linearized OM52 and OM53 plasmid DNA and with 1 microgram of pSV2DHFR (as before). Selection was carried out in G418 (Geneticin from Life Technologies Ltd), 10% dialysed fetal bovine serum (FBS) and Alpha DMEM medium. Supernatants from 24hr confluent cultures were tested in an antiviral assay using human fibroblasts (MRC5 line) and EMC virus as described in Example 2. The results are shown in Table 5.

Table 5

Plasmid	Antiviral Activity U/ml
OM52 (LAP-huIFN)	256
OM53 (huIFN-LAP)	0

Results

This data indicates that latency of the fusion protein cannot be predicted because human IFN β fused to LAP-MMP behaves differently to the mouse protein when fused to the LAP-MMP peptide. Whilst with the mouse sequence the LAP-MMP-IFN β conformation was latent, in the case of the human (OM52) this construct was

active and vice versa, i.e. the mouse IFN-LAP conformation was active whilst the human (OM53) was inactive.

Example 5

Collagen induced arthritis (CIA) and DNA injection

DBA/1 mice were immunised with collagen type II (CII) as described in Dreja, et al. Arthritis and Rheumatism, **43**, 1698-1708 (2000) and 3 weeks later were boosted with CII in incomplete Freund's adjuvant. 100 micrograms plasmid DNA in PBS was injected intramuscularly at 3 sites in the quadriceps, on the day of arthritis onset and mice were scored every other day for clinical arthritis and hind paw swelling was measured with calipers as described (Dreja, et al. Arthritis and Rheumatism, **43**, 1698-1708, (2000)).

In an arthritis model (CIA), the relative effectiveness of the latent cytokine (LAP-mIFN β) versus the active versions (PorcLAP-mIFN β and mIFN β -LAP) was measured. The latent LAP-mIFN β shows greater efficacy than either of the active moieties, mIFN β -LAP or PorcLAP-IFN β , as compared with the control treated with pCDNA3 empty plasmid vector.

It was found that when delivered by gene therapy by intramuscular injection the latent cytokine was more efficacious in the treatment of established disease.

Conclusions

It has been shown herein that an active cytokine molecule could be designed to become "latent" by addition of the latency domain of TGF β either at its NH₂ or COOH termini. The cytokine IFN β was used in the experimental models.

The LAP domain of TGF β conferred "latency" to IFN β which could be abrogated by incubating the fusion protein with MMPs. Possibly the latency has to do with steric hindrance by LAP on the interaction between the IFN β moiety with its cellular receptors. Despite the fact that both NH₂ and COOH ends of the molecule are in close proximity in the crystal structure of IFN β , a better 'shell' appeared to be

conferred by fusing the LAP domain at its NH₂ terminus as it is found in TGFβ itself. It is plausible that with other cytokines this may be different, depending on their tertiary structure and the surface of interaction with their receptors.

The MMP site located between LAP and IFNβ could be cleaved *in vitro* by MMP-3 and MMP-1. MMP-3 and MMP-1 have homologous regions in their active site (Massova et al., J. Mol. Model. **3**, 17-30 (1997)). It is quite plausible that other MMPs will also cleave this site as shown by the activation occurring in concentrated serum-free supernatants of CHO cells (Table 2). Expression of MMPs is very tightly regulated (Han et al., Autoimmunity, **28**, 197-208 (1998)). MMPs are active during tissue remodelling, wound healing and inflammation (Kubota et al., J. Oral & Maxillofacial Surgery, **55**, 20-27 (1997); Van Meurs et al., Arthritis & Rheumatism, **42**, 2074-2084 (1999); Leppert et al., Brain, **121**, 2327-2334 (1998); Uhm et al., Annals of Neurology, **46**, 319-324 (1999); Louis et al., Clin. Exp. Immunol. **120**, 241-246 (2000); Baugh et al., Gastroenterology, **117**, 814-822 (1999)). MMPs are also necessary for tumour cells to invade surrounding tissue. Indeed expression of tissue inhibitor of metalloproteinases (TIMPs) can inhibit tumour invasion and metastasis (DeClerck et al., Cancer Res. **52**, 701-708 (1992)).

MMP9 could not cleave the fusion proteins. Using fluorogenic peptide substrates with the sequence PLGLWA-d-R the value of rate of hydrolysis (kcat/Km) of matrix metalloproteinases appear to follow the order MMP9>MMP2>MMP7>MMP3>MMP1 (Nagase and Fields, Biopolymers, **40**, 399-416 (1996)). This discrepancy in hydrolysis sensitivity between the peptide substrate and the engineered proteins used in this study may be related to their tertiary structure.

The "latent" cytokine design appears to have several advantages. Firstly, upon administration the cytokine, it does not appear to be rapidly taken up by cells bearing its receptors, this may have impact on its toxicity and may provide for a longer half-life. LAP-containing TGFβ has been shown to have an increased half-life *in vivo* (Wakefield et al., J. Clin. Invest. **86**, 1976-1984 (1990)). Thus, as a consequence, therapeutic systemic administration could be dosed at lower concentrations.

Secondly, both LAP and LTBP may facilitate the interaction of the latent cytokine with the extracellular matrix.

Thirdly, the cytokine may not typically be released to interact with cellular receptors unless inflammatory or tissue remodelling processes are taking place involving MMP activity. Such activity is found in osteoarthritis, rheumatoid arthritis (Kubota et al., J. Oral & Maxillofacial Surgery, **55**, 20-27 (1997); Van Meurs et al., Arthritis & Rheumatism, **42**, 2074-2084 (1999); Singer et al., Osteoarthritis & Cartilage, **5**, 407-418 (1997)) and other types of chronic disease such as inflammatory bowel disease (Loius et al., Clin. Exp. Immunol, **120**, 241-246 (2000); Baugh et al., Gastroenterology, **117**, 814-822 (1999)), multiple sclerosis (Leppert et al., Brain, **121**, 2327-2334)), atherosclerosis (Libby, Vascular Medicine, **3**, 225-229 (1998)) and during cancer invasion (DeClerck et al., Cancer Res. **52**, 701-708 (1992)).

It could be argued that upon cleavage, the release of LAP could have antagonistic effects for TGF β , as it has been shown that *in vitro* LAP is capable of inhibiting active TGF β action (Wakefield et al., Growth Factors, **1**, 203-218 (1989)). However, it is expected that our LAP-fusion protein may exert its action at sites of inflammation where free radicals abound. It has been shown that nitrosylation of LAP disables its capacity for binding to TGF β (Vodovotz et al., Cancer Res. **59**, 2142-2149 (1999)). Thus it is unlikely that in sites of inflammation the released LAP will antagonise TGF β function.

Additional modifications to the MMP cleavage site may provide for additional tissue specificity.

CLAIMS

1. The use of a fusion protein comprising a latency associated peptide (LAP) and a proteolytic cleavage site for providing latency to a pharmaceutically active agent.
2. The use of a fusion protein comprising a latency associated peptide (LAP) and a proteolytic cleavage site for providing site-specific activation of a latent biologically active agent.
3. The use as claimed in claim 1 or claim 2, wherein the latency associated peptide comprises the precursor peptide of TGF β -1, 2, 3, 4 or 5.
4. The use as claimed in any of claims 1 to 3, wherein the proteolytic cleavage site is a matrix metalloproteinase (MMP) cleavage site.
5. The use as claimed in any one of the preceding claims wherein the pharmaceutically active agent is a growth factor, differentiation factor, cytokine, chemokine, trophic factor, cytokine inhibitor, cytokine receptor, free-radical scavenging enzyme, pro-drug converting enzyme, peptide mimetic, protease inhibitor, tissue inhibitor of metalloproteinase sub class, inhibitor of serine protease, chemotherapeutic agent or peptide nucleic acid sequence.
6. The use as claimed in any one of the preceding claims wherein the fusion protein is in association with latent TGF β binding protein.
7. A nucleic acid construct comprising a first nucleic acid sequence encoding a pharmaceutically active agent, a second nucleic acid sequence encoding a LAP, wherein a nucleic acid sequence encoding a proteolytic cleavage site is provided between the first and second nucleic acid sequences.
8. A nucleic acid construct as claimed in claim 7, wherein the LAP comprises the precursor peptide of TGF β -1, 2, 3, 4 or 5.

9. A nucleic acid construct as claimed in claim 7 or claim 8, wherein the proteolytic cleavage site is a matrix metalloproteinase (MMP) cleavage site.
10. A nucleic acid construct as claimed in any one of claims 7 to 9, wherein the pharmaceutically active agent is a growth factor, differentiation factor, cytokine, chemokine, trophic factor, cytokine inhibitor, cytokine receptor, free-radical scavenging enzyme, pro-drug converting enzyme, peptide mimetic, protease inhibitor, tissue inhibitor of metalloproteinase sub class, inhibitor of serine protease, chemotherapeutic agent or peptide nucleic acid sequence.
11. A nucleic acid construct as claimed 10 wherein the first nucleic acid sequence encodes the protein IFN β .
12. A nucleic acid construct as claimed in any one of claims 7 to 11 which is in the form of a vector.
13. A cell comprising a nucleic acid construct as claimed in any one of claims 7 to 12.
14. A protein which is the expression product of a nucleic acid construct as claimed in claims 7 to 12.
15. A method of treatment of a patient comprising administering to said patient a therapeutically effective amount of a nucleic acid construct as claimed in any one of claims 7 to 12.
16. A method as claimed in claim 14, wherein the patient is a human or non-human animal.
17. A method as claimed in claim 15 or 16, wherein the treatment is the treatment of an inflammatory disorder.
18. A method as claimed in any one of claims 15 or claim 17, wherein the treatment is gene therapy.

19. A nucleic acid construct as claimed in any one of claims 7 to 12 for use in medicine.
20. Use of a nucleic acid construct as claimed in any one of claims 7 to 12 in the manufacture of a medicament for the treatment of an inflammatory disorder.
21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a nucleic acid construct as claimed in any one of claims 7 to 12.
22. A fusion protein comprising a LAP and a proteolytic cleavage site wherein the fusion protein is associated with a pharmaceutically active agent.
23. A process for preparing a fusion protein as claimed in claim 22 comprising production of the fusion protein recombinantly by expression in a host cell, purification of the expressed fusion protein and association of the pharmaceutically active agent to the purified fusion protein by means of chemical cross linking.
24. A method of treatment of a patient comprising administering to said patient a therapeutically effective amount of a fusion protein as claimed in claim 22.
25. A fusion protein as claimed in claim 22 for use in medicine.
26. Use of a fusion protein as claimed in claim 22 in the manufacture of a medicament for the treatment of an inflammatory disorder.
27. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a fusion protein as claimed in claim 22.
28. A method of providing latency to a pharmaceutically active agent comprising associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with said pharmaceutically active agent.

29. A kit of parts comprising a nucleic acid construct as claimed in any one of claims 7 to 12, or a fusion protein as claimed in claim 22, and an administration vehicle.

1 / 19

FIG. 1

TGFB+MMP+ifn b Sequence

10	20	30	40	50	60	
1234567890	1234567890	1234567890	1234567890	1234567890	1234567890	
ATGCCGCCCT	CCGGGCTGCG	GCTGCTGCCG	CTGCTGCTAC	CGCTGCTGTG	GCTACTGGTG	60
MetProProS	erGlyLeuAr	gLeuLeuPro	LeuLeuLeuP	roLeuLeuTr	pLeuLeuVal	
CTGACGCCTG	GCCCCCGGC	CGCGGGACTA	TCCACCTGCA	AGACTATCGA	CATGGAGCTG	120
LeuThrProG	lyProProAl	aAlaGlyLeu	SerThrCysL	ysThrIleAs	pMetGluLeu	
GTGAAGCGGA	AGCGCATCGA	GGCCATCCGC	GGCCAGATCC	TGTCCAAGCT	GCGGCTCGCC	180
ValLysArgL	ysArgIleGl	uAlaIleArg	GlyGlnIleL	euSerLysLe	uArgLeuAla	
AGCCCCCGGA	GCCAGGGGGA	GGTGCCGCCC	GGCCCCGTGC	CCGAGGCCGT	GCTCGCCCTG	240
SerProProS	erGlnGlyGl	uValProPro	GlyProLeuP	roGluAlaVa	lLeuAlaLeu	
TACAACAGCA	CCCGCGACCG	GGTGGCCGGG	GAGAGTGCAG	AACCGGAGCC	CGAGCCTGAG	300
TyrAsnSerT	hrArgAspAr	gValAlaGly	GluSerAlaG	luProGluPr	oGluProGlu	
GCCGACTACT	ACGCCAAGGA	GGTCACCCGC	GTGCTAATGG	TGGAAACCCA	CAACGAAATC	360
AlaAspTyrT	yrAlaLysGl	uValThrArg	ValLeuMetV	alGluThrHi	sAsnGluIle	
TATGACAAGT	TCAAGCAGAG	TACACACAGC	ATATATATGT	TCTTCAACAC	ATCAGAGCTC	420
TyrAspLysP	heLysGlnSe	rThrHisSer	IleTyrMetP	hePheAsnTh	rSerGluLeu	
CGAGAAGCGG	TACCTGAACC	CGTGTGTGTC	TCCCGGGCAG	AGCTGCGTCT	GCTGAGGAGG	480
ArgGluAlaV	alProGluPr	oValLeuLeu	SerArgAlaG	luLeuArgLe	uLeuArgArg	
CTCAAGTTAA	AAGTGGAGCA	GCACGTGGAG	CTGTACCAGA	AATACAGCAA	CAATTCCTGG	540
LeuLysLeuL	ysValGluGl	nHisValGlu	LeuTyrGlnL	ysTyrSerAs	nAsnSerTrp	
CGATACCTCA	GCAACCGGCT	GCTGGCACCC	AGCGACTCGC	CAGAGTGGTT	ATCTTTTGAT	600
ArgTyrLeuS	erAsnArgLe	uLeuAlaPro	SerAspSerP	roGluTrpLe	uSerPheAsp	
GTCACCGGAG	TTGTGCGGCA	GTGGTTGAGC	CGTGGAGGGG	AAATTGAGGG	CTTTCGCCTT	660
ValThrGlyV	alValArgGl	nTrpLeuSer	ArgGlyGlyG	luIleGluGl	yPheArgLeu	
AGCGCCCACT	GCTCCTGTGA	CAGCAGGGAT	AACACACTGC	AAGTGGACAT	CAACGGGTTC	720
SerAlaHisC	ysSerCysAs	pSerArgAsp	AsnThrLeuG	lnValAspIl	eAsnGlyPhe	
ACTACCGGCC	GCCGAGGTGA	CCTGGCCACC	ATTCATGGCA	TGAACCGGCC	TTTCTGTGCT	780
ThrThrGlyA	rgArgGlyAs	pLeuAlaThr	IleHisGlyM	etAsnArgPr	oPheLeuLeu	
CTCATGGCCA	CCCCGCTGGA	GAGGGCCCAG	CATCTGCAAA	GCGAATTCCG	<u>GAGAGCGGGA</u>	840
LeuMetAlaT	hrProLeuGl	uArgAlaGln	HisLeuGlnS	erGluPheGl	yGlyGlyGly	
TCCCCGCTCG	GGCTTTGGGC	GGGAGGGGGC	TCA	SCGGCCG	CAATCAACTA	900
SerProLeuG	lyLeuTrpAl	aGlyGlyGly	SerAlaAlaA	laIleAsnTy	rLysGlnLeu	
CAGCTCCAAG	AAAGGACGAA	CATTCGAAAA	TGTCAGGAGC	TCCTGGAGCA	GCTGAATGGA	960
GlnLeuGlnG	luArgThrAs	nIleArgLys	CysGlnGluL	euLeuGluGl	nLeuAsnGly	

2 / 19

AAGATCAACC	TCACCTACAG	GGCGGACTTC	AAGATCCCTA	TGGAGATGAC	GGAGAAGATG	1020
LysIleAsnL	euThrTyrAr	gAlaAspPhe	LysIleProM	etGluMetTh	rGluLysMet	
CAGAAGAGTT	ACACTGCCTT	TGCCATCCAA	GAGATGCTCC	AGAATGTCTT	TCTTGTCTTC	1080
GlnLysSerT	yrThrAlaPh	eAlaIleGln	GluMetLeuG	lnAsnValPh	eLeuValPhe	
AGAAACAATT	TCTCCAGCAC	TGGGTGGAAT	GAGACTATTG	TTGTACGTCT	CCTGGATGAA	1140
ArgAsnAsnP	heSerSerTh	rGlyTrpAsn	GluThrIleV	alValArgLe	uLeuAspGlu	
CTCCACCAGC	AGACAGTGTT	TCTGAAGACA	GTACTAGAGG	AAAAGCAAGA	GGAAAGATTG	1200
LeuHisGlnG	lnThrValPh	eLeuLysThr	ValLeuGluG	luLysGlnGl	uGluArgLeu	
ACGTGGGAGA	TGTCCTCAAC	TGCTCTCCAC	TTGAAGAGCT	ATTACTGGAG	GGTGCAAAGG	1260
ThrTrpGluM	etSerSerTh	rAlaLeuHis	LeuLysSerT	yrTyrTrpAr	gValGlnArg	
TACCTTAAAC	TCATGAAGTA	CAACAGCTAC	GCCTGGATGG	TGGTCCGAGC	AGAGATCTTC	1320
TyrLeuLysL	euMetLysTy	rAsnSerTyr	AlaTrpMetV	alValArgAl	aGluIlePhe	
AGGAACTTTC	TCATCATTCG	AAGACTTACC	AGAACTTCC	AAAAGTATC	TAGACC	1376
ArgAsnPheL	euIleIleAr	gArgLeuThr	ArgAsnPheG	lnAsn***Se	rArg	
				uga		

FIG. 1 CONT'D

ifn+MMP+TGFb Sequence

[illegible]

4 / 19

```

GTGTTGCTCT CCCGGGCACA GCTGCGTCTG CTGAGGAGGC TCAAGTTAAA AGTGGAGCAG 1020
ValLeuLeuS erArgAlaGl uLeuArgLeu LeuArgArgL euLysLeuLy sValGluGln

CACGTGGAGC TGTACCAGAA ATACAGCAAC AATTCCTGGC GATACCTCAG CAACCGGCTG 1080
HisValGluL euTyrGlnLy sTyrSerAsn AsnSerTrPA rgTyrLeuSe rAsnArgLeu

CTGGCACCCA GCGACTCGCC AGAGTGGTTA TCTTTTGATG TCACCGGAGT TGTGCGGCAG 1140
LeuAlaProS erAspSerPr oGluTrpLeu SerPheAspV alThrGlyVa lValArgGln

TGTTTGAGCC GTGGAGGGGA AATTGAGGGC TTTCGCCTTA GCGCCCACTG CTCCTGTGAC 1200
TrpLeuSerA rgGlyGlyGl uIleGluGly PheArgLeuS erAlaHisCy sSerCysAsp

AGCAGGGATA ACACACTGCA AGTGGACATC AACGGGTTCA CTACCGGCCG CCGAGGTGAC 1260
SerArgAspA snThrLeuGl nValAspIle AsnGlyPheT hrThrGlyAr GArgGlyAsp

CTGGCCACCA TTCATGGCAT GAACCGGCCT TTCCTGCTTC TCATGGCCAC CCCGCTGGAG 1320
LeuAlaThrI leHisGlyMe tAsnArgPro PheLeuLeuL euMetAlaTh rProLeuGlu

AGGGCCCAGC ATCTGCAAAG GtgaTCTAGA CC 1352
ArgAlaGlnH isLeuGlnSe r...SerArg

```

FIG. 2 CONT'D

SUBSTITUTE SHEET (RULE 26)

		200	220	240	
Hu	TGF-β 1	WLSFDVTGVVRQWLSRGGEIEGFRLSAHCSG-----DSRDNTLQVDIN-GFTTGR-----RGDLATI-----			
Hu	TGF-β 2	WLSFDVTDVAVHEWLHHKDRWLGFKISLHCPCCTFVPSNNYIIPNKSEEEARFA-GIDGTSTYTSQDKTIKSTRK			
Hu	TGF-β 3	WLSFDVTDVREWLLRRRESNLGLEISIHCPCHTFQP-NGDILENIHEVMEIKFK-GVDNEDDHGRDGLRLK---K			
Ck	TGF-β 4	WLSFDVTDVAVHQWLSGSELIGVFKL SVHCPCEMGP-G-HADEMRISIEGFFEOQ-----RGDMQSI A---K			
Fg	TGF-β 5	WNSFDVTTKTVNEWLKR A ENEQFGLQPAKG-----PTPQAKD-----IDIEGFPAL-RGDLASL---SSK			
		+ +++++ + ++	* *	++	
		260	↓ 280	300	
Hu	TGF-β 1	-----HGMWRPFLLIMATPLERA-QK--LQSS---RHRRALDTNYCFST--EKNCCVRQLYIDFRKDLGWKWIHEP			
Hu	TGF-β 2	KNSGKT---PHLLMLLPSYRL-ESQ-----QTNRRKKRALDAAYCFERNV--QDNCCLRPLYIDFKRDLGWKWIHEP			
Hu	TGF-β 3	QKDNN--N-PHLILMMIPPHRL-DNPGQGQ---RKKRALDTNYCFRNL--EENCCVRPLYIDFRQDLGWKWIHEP			
Ck	TGF-β 4	-KHRR--V-PYVLAMALPAERANE---LHSA---RRRRLD TDYCFGPGTDEKNCCVRPLYIDFRKDLQWKWIHEP			
Fg	TGF-β 5	ENT-----KPYL--MITMPPAERIDTVT SS---RKKRGVGQ EYCFGN--GPNCCVKPL YINFRKDLGWKWIHEP			
		+ + + + + + + +	+ + + + + + + +	+ + + + + + + +	
		320	340	360	380 390
Hu	TGF-β 1	KGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYVGRKPKVEQLSNMIVRSCKCS			
Hu	TGF-β 2	KGYNANFCAGACPYIWSSTDQHSRVLSLYNTINPEASAPCCVSDLEPLTILYIGKIPKIEQLSNMIVKSKCS			
Hu	TGF-β 3	KGYANFCSGCPYIWSADTTHSTVLGLYNTLNPEASAPCCVPQDLPLTILYVGRIPKVEQLSNMIVKSKCS			
Ck	TGF-β 4	KGYMANFCMGPCPYIWSADTQYIKVLALYNQHNPGASAAPCCVPQILDPLPIIYVGRNVVRVEQLSNMIVRACKCS			
Fg	TGF-β 5	KGYEANYCIGNCPYIWSMDTQYSKVLSLYNQHNPGASISPCCVPDVLEPLPIIYVVGRIAKVEQLSNMIVRSCNCS			
		+++ ++ * + *+++ + ++	++ +++ ++ ++	+ + + + + + + +	+ * + +

FIG. 3 CONT'D

FIG. 4

Protein	Sequence	Reference
MMP-1/MMP-8		
Human type I collagen ($\alpha 1$)	Ala-Pro-Gln-Gly ₇₇₅ ~Ile ₇₇₆ -Ala-Gly-Gln	80
Human type I collagen ($\alpha 2$)	Gly-Pro-Gln-Gly ₇₇₅ ~Leu ₇₇₆ -Leu-Gly-Ala	80
Human type II collagen	Gly-Pro-Gln-Gly ₇₇₅ ~Leu ₇₇₆ -Ala-Gly-Gln	80
Human type III collagen	Gly-Pro-Leu-Gly ₇₇₅ ~Ile ₇₇₆ -Ala-Gly-Ile	80
Human α_2 -macroglobulin	Gly-Pro-Glu-Gly ₆₇₉ ~Leu ₆₈₀ -Arg-Val-Gly	84
Rat α_2 -macroglobulin	Ala-Ala-Tyr-His ₆₈₁ ~Leu ₆₈₂ -Val-Ser-Gin	84
Rat α_2 -macroglobulin	Met-Asp-Ala-Phe ₆₉₁ ~Leu ₆₉₂ -Glu-Ser-Ser	84
Rat α_1 -macroglobulin	Glu-Pro-Gln-Ala ₆₈₃ ~Leu ₆₈₄ -Ala-Met-Ser	84
Rat α_1 -macroglobulin	Gln-Ala-Leu-Ala ₆₈₅ ~Met ₆₈₆ -Ser-Ala-Ile	84
Chicken ovostatin	Pro-Ser-Tyr-Phe ₆₇₃ ~Leu ₆₇₄ -Asn-Ala-Gly	79
Human pregnancy zone protein	Tyr-Glu-Ala-Gly ₆₈₅ ~Leu ₆₈₆ -Gly-Val-Val	84
Human pregnancy zone protein	Ala-Gly-Leu-Gly ₆₈₇ ~Val ₆₈₈ -Val-Glu-Arg	84
Human pregnancy zone protein	Ala-Gly-Leu-Gly ₇₅₇ ~Ile ₇₅₈ -Ser-Ser-Thr	84
α_1 -protease inhibitor	Gly-Ala-Met-Phe ₃₅₂ ~Leu ₃₅₃ -Glu-Ala-Ile	85
Human aggrecan	Ile-Pro-Glu-Asn ₃₄₁ ~Phe ₃₄₂ -Phe-Gly-Val	86
Human aggrecan	Thr-Glu-Gly-Glu ₃₇₃ ~Ala ₃₇₄ -Arg-Gly-Ser	86
Human cartilage link	Arg-Ala-Ile-His ₁₆ ~Ile ₁₇ -Gln-Ala-Glu	87
Human insulin-like growth factor binding protein-3	Leu-Arg-Ala-Tyr ₉₉ ~Leu ₁₀₀ -Leu-Pro-Ala	88
MMP-2		
Guinea pig $\alpha 1(I)$ gelatin	Gly-Ala-Hyp-Gly ₅₄₇ ~Leu ₅₄₈ -Glx-Gly-His	24
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Gln-Gly ₁₉₀ ~Val ₁₉₁ -Arg-Gly-Glu	30
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Ala-Gly ₂₇₇ ~Val ₂₇₈ -Gln-Gly-Pro	30
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Ser-Gly ₃₀₁ ~Leu ₃₀₂ -Hyp-Gly-Pro	30
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Ala-Gly ₃₃₁ ~Glu ₃₃₂ -Arg-Gly-Ser	30
Rat $\alpha 1(I)$ gelatin	Gly-Ala-Lys-Gly ₃₆₁ ~Leu ₃₆₂ -Thr-Gly-Ser	30
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Ala-Gly ₃₈₂ ~Gln ₃₈₃ -Asp-Gly-Pro	30
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Ala-Gly ₆₃₄ ~Phe ₆₃₅ -Ala-Gly-Pro	30
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Ile-Gly ₆₇₆ ~Asn ₆₇₇ -Val-Gly-Ala	30
Rat $\alpha 1(I)$ gelatin	Gly-Pro-Hyl-Gly ₆₈₅ ~Ser ₆₈₆ -Arg-Gly-Ala	30
Bovine type 1 collagen ($\alpha 1$)	Gly-Pro-Gln-Gly ₇₇₅ ~Ile ₇₇₆ -Ala-Gly-Gln	22
Bovine type 1 collagen ($\alpha 2$)	Gly-Pro-Gln-Gly ₇₇₅ ~Leu ₇₇₆ -Leu-Gly-Ala	22
Human aggrecan	Ile-Pro-Glu-Asn ₃₄₁ ~Phe ₃₄₂ -Phe-Gly-Val	89
Human galectin-3	Pro-Pro-Gly-Ala ₆₂ ~Tyr ₆₃ -His-Gly-Ala	90
Human cartilage link	Arg-Ala-Ile-His ₁₆ ~Ile ₁₇ -Gln-Ala-Glu	87
Human cartilage link	Gly-Pro-His-Leu ₂₅ ~Leu ₂₆ -Val-Glu-Ala	87
Human insulin-like growth factor binding protein-3	Leu-Arg-Ala-Tyr ₉₉ ~Leu ₁₀₀ -Leu-Pro-Ala	88

MMP-3		
Human α_2 -macroglobulin	Gly-Pro-Glu-Gly ₆₇₉ ~Leu ₆₈₀ -Arg-Val-Gly	79
Human α_2 -macroglobulin	Arg-Val-Gly-Phe ₆₈₄ ~Tyr ₆₈₅ -Glu-Ser-Asp	79
Human α_1 -antichymotrypsin	Leu-Leu-Ser-Ala ₃₆₀ ~Leu ₃₆₁ -Val-Glu-Thr	91
α_1 -protease inhibitor	Glu-Ala-Ile-Pro ₃₅₇ ~Met ₃₅₈ -Ser-Ile-Pro	91
Antithrombin III	Ile-Ala-Gly-Arg ₃₈₅ ~Ser ₃₈₆ -Leu-Asn-Pro	91
Chicken ovostatin	Leu-Asn-Ala-Gly ₆₇₇ ~Phe ₆₇₈ -Thr-Ala-Ser	79, 92
Human aggrecan	Ile-Pro-Glu-Asn ₃₄₁ ~Phe ₃₄₂ -Phe-Gly-Val	93
Substance P	Lys-Pro-Gln-Gln ₆ ~Phe ₇ -Phe-Gly-Leu	37
Human ProMMP-1	Asp-Val-Ala-Gln ₈₀ ~Phe ₈₁ -Val-Leu-Thr	43
Human ProMMP-3	Asp-Thr-Leu-Glu ₆₈ ~Val ₆₉ -Met-Arg-Lys	94
Human ProMMP-3	Asp-Val-Gly-His ₈₂ ~Phe ₈₃ -Arg-Thr-Phe	94
Human ProMMP-8	Asp-Ser-Gly-Gly ₇₈ ~Phe ₇₉ -Met-Leu-Thr	95
Human ProMMP-9	Arg-Val-Ala-Glu ₄₀ ~Met ₄₁ -Arg-Gly-Glu	48
Human ProMMP-9	Asp-Leu-Gly-Arg ₈₇ ~Phe ₈₈ -Gln-Thr-Phe	48
Human fibronectin	Pro-Phe-Ser-Pro ₆₈₉ ~Leu ₆₉₀ -Val-Ala-Thr	21
Human insulin-like growth factor binding protein-3	Leu-Arg-Ala-Tyr ₉₉ ~Leu ₁₀₀ -Leu-Pro-Ala	88
	Ala-Pro-Gly-Asn ₁₀₉ ~Ala ₁₁₀ -Ser-Glu-Ser	88
	Phe-Ser-Ser-Glu ₁₇₆ ~Ser ₁₇₇ -Lys-Arg-Glu	88
Bovine $\alpha 1$ (II) collagen, N-telopeptide	Ala-Gly-Gly-Ala ₁₁₅ ~Gln ₁₁₆ -Met-Gly-Val	96
Bovine $\alpha 1$ (II) collagen, N-telopeptide	Gln-Met-Gly-Val ₁₁₉ ~Met ₁₂₀ -Gln-Gly-Pro	96
Bovine $\alpha 1$ (IX) collagen, NC2	Met-Ala-Ala-Ser~Leu-Lys-Arg-Pro	96
Bovine $\alpha 2$ (IX) collagen, NC2	~Ala-Lys-Arg-Glu	96
Bovine $\alpha 3$ (IX) collagen, NC2	~Leu-Arg-Lys-Pro	96
Bovine $\alpha 1$ (XI) collagen, N-telopeptide	Gln-Ala-Gln-Ala~Ile-Leu-Gln-Gln	96
Human cartilage link	Arg-Ala-Ile-His ₁₆ ~Ile ₁₇ -Gln-Ala-Glu	87
Bovine insulin, B chain	Leu-Val-Glu-Ala ₁₄ ~Leu ₁₅ -Tyr-Leu-Val	97
Bovine insulin, B chain	Glu-Ala-Leu-Tyr ₁₆ ~Leu ₁₇ -Val-Cys-Gly	21, 97
MMP-7		
Human aggrecan	Ile-Pro-Glu-Asn ₃₄₁ ~Phe ₃₄₂ -Phe-Gly-Val	89
Human cartilage link	Gly-Pro-His-Leu ₂₅ ~Leu ₂₆ -Val-Glu-Ala	87
Human prourokinase	Pro-Pro-Glu-Glu ₁₄₃ ~Leu ₁₄₄ -Lys-Phe-Gln	98
MMP-9		
Human type V collagen ($\alpha 1$)	Gly-Pro-Pro-Gly ₄₃₉ ~Val ₄₄₀ -Val-Gly-Pro	99
Human type V collagen ($\alpha 2$)	Gly-Pro-Pro-Gly ₄₄₅ ~Leu ₄₄₆ -Arg-Gly-Glu	99
Human type XI collagen ($\alpha 1$)	Gly-Pro-Gly-Gly ₄₃₉ ~Val ₄₄₀ -Val-Gly-Pro	99
Human aggrecan	Ile-Pro-Glu-Asn ₃₄₁ ~Phe ₃₄₂ -Phe-Gly-Val	89
Human galectin-3	Pro-Pro-Gly-Ala ₆₂ ~Tyr ₆₃ -His-Gly-Ala	90
Human cartilage link	Arg-Ala-Ile-His ₁₆ ~Ile ₁₇ -Gln-Ala-Glu	87
MMP-10		
Human cartilage link	Arg-Ala-Ile-His ₁₆ ~Ile ₁₇ -Gln-Ala-Glu	87
Human cartilage link	Gly-Pro-His-Leu ₂₅ ~Leu ₂₆ -Val-Glu-Ala	87

FIG. 4 CONT'D

9 / 19





FIG. 5

10 / 19






FIG. 7




FIG. 8a

Anti-LAP	+	+	+	+	-	-	-	-
Anti-IFN	-	-	-	-	+	+	+	+
MMP1	-	+	-	-	-	+	-	-
MMP3	-	-	+	-	-	-	+	-
SF	-	-	-	+	-	-	-	+
M.W.	1	2	3	4	5	6	7	8




FIG. 8b

14 / 19





FIG. 9

15 / 19




FIG. 10

16 / 19

FIG. 11

huIFN-LAP -> 1-phase Translation

DNA Sequence 1352b.p. ATGAACAACAGG ... CTGATCTAGACC linear

```

1      /      1                               31      /      11
ATG AAC AAC AGG TGG ATC CTC CAC GCT GCG TTC CTG CTG TGC TTC TCC ACC ACA GCC CTC
met asn asn arg trp ile leu his ala ala phe leu leu cys phe ser thr thr ala leu
61    /      21                               91    /      31
TCC ATC AAC TAT AAG CAG CTC CAG CTC CAA GAA AGG ACG AAC ATT CGG AAA TGT CAG GAG
ser ile asn tyr lys gln leu gln leu gln glu arg thr asn ile arg lys cys gln glu
121   /      41                               151   /      51
CTC CTG GAG CAG CTG AAT GGA AAG ATC AAC CTC ACC TAC AGG GCG GAC TTC AAG ATC CCT
leu leu glu gln leu asn gly lys ile asn leu thr tyr arg ala asp phe lys ile pro
181   /      61                               211   /      71
ATG GAG ATG ACG GAG AAG ATG CAG AAG AGT TAC ACT GCC TTT GCC ATC CAA GAG ATG CTC
met glu met thr glu lys met gln lys ser tyr thr ala phe ala ile gln glu met leu
241   /      81                               271   /      91
CAG AAT GTC TTT CTT GTC TTC AGA AAC AAT TTC TCC AGC ACT GGG TGG AAT GAG ACT ATT
gln asn val phe leu val phe arg asn asn phe ser ser thr gly trp asn glu thr ile
301   /     101                               331   /     111
GTT GTA CGT CTC CTG GAT GAA CTC CAC CAG CAG ACA GTG TTT CTG AAG ACA GTA CTA GAG
val val arg leu leu asp glu leu his gln gln thr val phe leu lys thr val leu glu
361   /     121                               391   /     131
GAA AAG CAA CAG GAA AGA TTG ACG TGG GAG ATG TCC TCA ACT GCT CTC CAC TTG AAG AGC
glu lys gln glu glu arg leu thr trp glu met ser ser thr ala leu his leu lys ser
421   /     141                               451   /     151
TAT TAC TGG AGG GTG CAA AGG TAC CTT AAA CTC ATG AAG TAC AAC AGC TAC GCC TGG ATG
tyr tyr trp arg val gln arg tyr leu lys leu met lys tyr asn ser tyr ala trp met
481   /     161                               511   /     171
GTG GTC CGA GCA GAG ATC TTC AGG AAC TTT CTC ATC ATT CGA AGA CTT ACC AGA AAC TTC
val val arg ala glu ile phe arg asn phe leu ile ile arg arg leu thr arg asn phe
541   /     181                               571   /     191
CAA AAC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG
gln asn glu phe gly gly gly gly ser pro leu gly leu trp ala gly gly gly ser ala
601   /     201                               631   /     211
GCC GCA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAT CTT AAG CGC ATC GAG
ala ala leu ser thr cys lys thr ile asp met glu leu val lys arg lys arg ile glu
661   /     221                               691   /     231
GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG
ala ile arg gly gln ile leu ser lys leu arg leu ala ser pro pro ser gln gly glu
721   /     241                               751   /     251
GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG
val pro pro gly pro leu pro glu ala val leu ala leu tyr asn ser thr arg asp arg
781   /     261                               811   /     271
GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC AAG GAG
val ala gly glu ser ala glu pro glu pro glu pro glu ala asp tyr tyr ala lys glu
841   /     281                               871   /     291
GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG AGT
val thr arg val leu met val glu thr his asn glu ile tyr asp lys phe lys gln ser

```

17 / 19

```

901 / 301                                931 / 311
ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC
thr his ser ile tyr met phe phe asn thr ser glu leu arg glu ala val pro glu pro
961 / 321                                991 / 331
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG
val leu leu ser arg ala glu leu arg leu leu arg arg leu lys leu lys val glu gln
1021 / 341                               1051 / 351
CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG
his val glu leu tyr gln lys tyr ser asn asn ser trp arg tyr leu ser asn arg leu
1081 / 361                               1111 / 371
CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG
leu ala pro ser asp ser pro glu trp leu ser phe asp val thr gly val val arg gln
1141 / 381                               1171 / 391
TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC
trp leu ser arg gly gly glu ile glu gly phe arg leu ser ala his cys ser cys asp
1201 / 401                               1231 / 411
AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC
ser arg asp asn thr leu gln val asp ile asn gly phe thr thr gly arg arg gly asp
1261 / 421                               1291 / 431
CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG
leu ala thr ile his gly met asn arg pro phe leu leu leu met ala thr pro leu glu
1321 / 441
AGG GCC CAG CAT CTG CAA AGC TGA TCT AGA
arg ala gln his leu gln ser OPA ser arg

```

FIG. 11 CONT'D

DNA Sequence 1391b.p. ATGCCGCCCTCC ... CTGATCTAGACC linear

SUBSTITUTE SHEET (RULE 26)

19 / 19

```

901 / 301                                931 / 311
GGA TTC CTA CAA AGA AGC AGC AAT TTT CAG TGT CAG AAG CTC CTG TGG CAA TTG AAT GGG
gly phe leu gln arg ser ser asn phe gln cys gln lys leu leu trp gln leu asn gly
961 / 321                                991 / 331
AGG CTT GAA TAT TGC CTC AAG GAC AGG ATG AAC TTT GAC ATC CCT GAG GAG ATT AAG CAG
arg leu glu tyr cys leu lys asp arg met asn phe asp ile pro glu glu ile lys gln
1021 / 341                               1051 / 351
CTG CAG CAG TTC CAG AAG GAG GAC GCC GCA TTG ACC ATC TAT GAG ATG CTC CAG AAC ATC
leu gln gln phe gln lys glu asp ala ala leu thr ile tyr glu met leu gln asn ile
1081 / 361                               1111 / 371
TTT GCT ATT TTC AGA CAA GAT TCA TCT AGC ACT GGC TGG AAT GAG ACT ATT GTT GAG AAC
phe ala ile phe arg gln asp ser ser ser thr gly trp asn glu thr ile val glu asn
1141 / 381                               1171 / 391
CTC CTG GCT AAT GTC TAT CAT CAG ATA AAC CAT CTG AAG ACA GTC CTG GAA GAA AAA CTG
leu leu ala asn val tyr his gln ile asn his leu lys thr val leu glu glu lys leu
1201 / 401                               1231 / 411
GAG AAA GAA GAT TTT ACC AGG GGA AAA CTC ATG AGC AGT CTG CAC CTG AAA AGA TAT TAT
glu lys glu asp phe thr arg gly lys leu met ser ser leu his leu lys arg lys leu
1261 / 421                               1291 / 431
GGG AGG ATT CTG CAT TAC CTG AAG GCC AAG GAG TAC AGT CAC TGT GCC TGG ACC ATA GTC
gly arg ile leu his tyr leu lys ala lys glu tyr ser his cys ala trp thr ile val
1321 / 441                               1351 / 451
AGA GTG GAA ATC CTA AGG AAC TTT TAC TTC ATT AAC AGA CTT ACA GGT TAC CTC CGA AAC
arg val glu ile leu arg asn phe tyr phe ile asn arg leu thr gly tyr leu arg asn
1381 / 461
TGA TCT AGA
OPA ser arg

```

FIG. 12 CONT'D